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List of abbreviations: 
 
ACE Inhibitors Angiotensin-converting enzyme inhibitors 
AMI/MI 
AR 
Acute myocardial infarction 
Additive risk-reduction 
ARB Angiotensin receptor blocker 
BMI Body mass index 
CABG Coronary artery bypass graft 
CAD Coronary artery disease 
CFR Case fatality rates 
CHD Coronary heart disease 
CMF Comparative mortality factor 
CPR Cardiopulmonary resuscitation 
CR Combined/cumulative risk-reduction 
DG Disease Group 
DPP 
GBD 
Deaths prevented or postponed 
Global burden of disease 
GPRD General practice research database 
HES Hospital episode statistics 
HF Heart failure 
HSfE Health survey for England 
ICD International classification of diseases 
IMD Index of multiple deprivation 
ISD Information Services Division 
MINAP Myocardial ischaemia national audit project 
NHANES National health and nutrition examination survey 
NHS National health service 
NSTEACS Non-ST elevation acute coronary syndrome 
NSTEMI Non-ST elevation myocardial infarction 
ONS Office for National Statistics 
OPCS codes  Office of Population Censuses and Surveys classification of surgical 
operations and procedures (used in HES) 
PARF Population attributable risk fraction 
PCI Percutaneous coronary intervention 
PCCIUR Primary Care Clinical Informatics Unit 
PG IIB/IIIA Platelet glycoprotein IIB/IIIA inhibitors 
PTCA Percutaneous transluminal coronary angioplasty 
RR Relative risk 
RRR Relative risk reduction 
SBP Systolic blood pressure 
SE Standard error 
SEC 
SHeS 
SIMD 
Socio-economic circumstances 
Scottish Health Survey  
Scottish Index of Multiple Deprivation 
SMR01 Scottish Morbidity Records database 01 
STEMI ST-elevation myocardial infarction 
UA 
WHO 
Unstable angina  
World Health Organization 
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1 Overview of the IMPACTSEC model  
 
1.1 INTRODUCTION 
 
This technical appendix is based on the technical report for the IMPACTSEC model 
created using English data.1 We have adapted their model to create the Scottish 
IMPACTSEC model. However, much of the theory and methods remain.  
 
IMPACT is a deterministic, cell-based policy model. It uses epidemiological information 
to estimate the contributions of population-level risk factor changes (impacting mainly 
on incidence) and changes in the uptake of evidence-based treatments (impacting 
mainly on case fatality) on mortality decline between two points in time (the start-year 
and the end-year).  The primary outcome measure of the model is the deaths 
prevented or postponed (DPPs).  
The starting point for the model is to calculate the ‘target’ number of deaths the model 
needs to explain. This target number is obtained by using death counts recorded in the 
official registration system to calculate the difference between the actual observed 
Coronary Heart Disease (CHD) deaths recorded in the end-year and the deaths 
expected in the end-year had the CHD mortality rates remained the same as in the 
start-year (i.e. simple direct standardisation). 
The calculation of the modelled estimate of DPPs rests on utilising two well-studied 
relationships: firstly, that between risk factor change and the relative reduction in CHD 
mortality; secondly, that between treatment uptake and reductions in case-fatality in 
patients with a specific form of CHD.  
The model applies the relative risk reduction quantified in previous randomised 
controlled trials and meta-analyses to estimate the mortality reduction attributable to:  
a) temporal change in risk factor prevalence (in those without diagnosed CHD) to 
calculate the DPPs ‘explained’ by specific risk factor trends;  
b) net change over the period in the uptake of specific treatments in patients with each 
specific form of CHD to estimate DPPs ‘explained’ owing to improved 1-year case 
fatality rates. Great care is taken to avoid double counting the same individuals. 
The mortality benefits from the risk factor reduction in the population, and the 
treatment benefits in patient groups are then summed. Thus summing uses a 
cumulative approach (rather than an additive approach), in order to avoid double-
counting of benefits in the same individual. (This approach is detailed in Section 1.3). 
This mortality sum represents the deaths prevented or postponed (DPPs) ‘explained’ 
by the model. 
At the end of the modelling process, the total DPPs ‘explained’ by the model is then 
compared with the observed fall in deaths (the ‘target’ to be explained).   
Model fit is therefore calculated as the difference between the observed deaths and 
model DPPs, and expressed as the percentage explained. This measures the extent to 
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which the model was successful in explaining the observed change in CHD mortality in 
the population.  
A policy model like IMPACT thus stands in contrast to a typical multivariate regression 
model.  A typical multivariate regression model represents a statistical approach to 
describing a single data-set, for instance generated by a single cohort or randomised 
controlled trial. In contrast, a policy model such as IMPACT seeks to integrate and 
synthesise best estimates from a variety of sources to reliably estimate the extent to 
which a range of factors, acting in combination, explain or predict an outcome.  We did 
not obtain the parameters for this model by running regressions. Rather, the model 
incorporates the best coefficients from the largest meta-analysis or randomised 
controlled trials of the reduction in case fatality attributed to treatment or the 
independent effect sizes of a unit change in each risk factor on CHD mortality.   
Examples of the calculation method used for estimating the DPPs due to treatment 
uptake (Example 1) and for continuous and binary risk factor change (Examples 2 and 
3, respectively) are provided below. Earlier versions of the IMPACT mortality model 
have been previously applied to national data from Europe, United States, Ontario, 
New Zealand and China.2-6 The methodology has previously been described in detail 
online and elsewhere.3-5 
 
The IMPACTSEC model 
We have now extended the IMPACT model to accommodate sub-national variation in 
CHD mortality trends by socioeconomic circumstances (IMPACTSEC model). The tables 
included in this supplementary appendix provide details about the sources and 
methods that were used in extending the IMPACT model to accommodate 
socioeconomic circumstances (IMPACTSEC model). We used the Scottish Index of 
Multiple Deprivation (SIMD) 2009 quintiles as a proxy indicator of socioeconomic 
circumstances. This model examines the effects of changes in treatment uptake and 
risk factor trends on changes in mortality from coronary heart disease (CHD) among 
adults in Scotland aged 25 years and over.  
 
 
1.2 METHOD AND EXAMPLES OF DEATHS PREVENTED OR POSTPONED (DPP) 
CALCULATIONS  
 
 
1.2.1 Changes in mortality rates from CHD, Scotland 2000 to 2010 
Data sources used in examining the changes in CHD mortality rates over 2000 to 2010 
are shown in Table A. Mortality rates from CHD were calculated using the underlying 
cause of death (2000: ICD9 410-414 and 429; 2010: ICD10 I20-I25). Both unadjusted 
and age-adjusted mortality rates were calculated. Rates are standardised to the 
European Standard Population aged 25+ years using direct standardisation. 
 
1.2.2 Expected and observed number of deaths from CHD 
Data sources used to estimate the observed and expected number of deaths from CHD 
for 2000 and 2010 are shown in Table A. The expected number of CHD deaths in 2010 
was calculated by multiplying the age-sex-SIMD quintile specific mortality rates from 
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CHD in 2000 by the population counts for 2010 in that age-sex-SIMD quintile stratum. 
Summing over all strata then yielded the expected number of deaths in 2010 had 
mortality rates remained unchanged. The difference between the number of expected 
and observed deaths from CHD represented the mortality fall, or the total number of 
deaths prevented or postponed (DPP), in 2010 relative to 2000. Population counts, 
CHD mortality rates, observed and expected numbers of deaths are shown in Table E.  
 
1.2.3 Treatment component of IMPACTSEC model 
The treatment component of the IMPACTSEC model included nine mutually exclusive 
CHD patient groups: 
 
 Patients treated in hospital for acute myocardial infarction (ST-elevation myocardial 
infarction and non-ST elevation acute coronary syndrome)  
 Patients admitted to hospital with unstable angina  
 Community-dwelling patients who have survived a myocardial infarction since 1981 
 Patients who have undergone a revascularisation procedure: Coronary Artery 
Bypass Grafting (CABG) (since 1981), or a Percutaneous Coronary Intervention 
(PCI) (since 1989). 
 Community-dwelling patients with stable coronary artery disease  
 Patients admitted to hospital with heart failure (associated with CHD)  
 Community-dwelling patients with heart failure (associated with CHD)  
 Hypercholesterolaemic subjects without CHD eligible for cholesterol lowering 
therapy such as statins 
 Hypertensive individuals without CHD eligible for anti-hypertensive therapy 
 
ST-segment and non-ST segment elevation myocardial infarction (STEMI and non-
STEMI respectively) patients were examined separately as the management and 
outcomes of these entities differ markedly7. 
  
In order to minimise double counting, major efforts were made to ensure that patients 
counted in each CHD patient group were mutually exclusive. These approaches are 
detailed later, in Table N.  
 
The data sources used to estimate the size of each treatment group (stratified by age-
sex-SIMD quintile) are shown in Table A. For each group, we estimated the number of 
DPPs that were attributable to various treatments. A list of the treatments considered 
in the model and the data sources used to estimate the percentage of patients 
receiving treatments is shown in Table B.  
 
The general approach to calculating the number of DPPs from an intervention among a 
particular patient group was first to stratify by age, sex and SEC, then to multiply the 
estimated number of patients in 2010 by the proportion of these patients receiving a 
particular treatment, by the one-year case fatality rate, and by the relative reduction 
in the case fatality rate due to the administered treatment. Sources for treatment 
uptake are shown in Table B. Sources for estimates of treatment efficacy (relative risk 
reductions) are shown in Table F. We obtained the relative risks based on the most 
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recent published systematic reviews and meta-analyses of epidemiological studies. 
Each treatment relative risk value in the model was based on a meta-analysis 
comparison with an older therapy, or in some cases with a placebo if relevant. Age-sex 
specific case fatality rates for each patient group are presented in Table G. Linked 
hospital admission and death data were used to calculate historical case fatality rates 
in Scotland where possible. The year 1986 was chosen as baseline as it is before most 
of the major changes in therapy/diagnosis were brought in and gives the ability to 
retrospectively exclude pre-existing cases of CHD. Linked data permits individual cases 
to be followed for 0 to 365 days allowing calculation of rates for the following disease 
groups: AMI; ACS; and Heart failure in hospital. Further, case fatality rates were 
calculated using 1995 as the baseline, namely: Post MI and post revascularisation (no 
MI) (separately for CABG and PTCA). Previously published data6 was used for the 
remaining disease groups where Scottish data was not available to calculate rates. 
 
It was assumed that compliance (adherence), i.e. the proportion of treated patients 
actually taking therapeutically effective levels of medication, was 100% among hospital 
patients, 70% among symptomatic community patients, and 50% among 
asymptomatic community patients taking lipid-lowering drugs or anti-hypertensive 
medication for primary prevention. An adjustment was also made in certain cases for 
sub-optimal dose.  
 
Note that Examples 1-5 are taken directly from the technical appendix of the English 
IMPACTSEC model1 hence use English data and time points (start year 2000, end year 
2007) in the calculations. 
 
EXAMPLE 1: Estimation of DPPs from a specific treatment 
 
Mortality fall in STEMI patients as a result of taking aspirin in men aged 55-64 in the 
most affluent quintile (in England) 
 
For example, in England in 2007, about 1,410 men aged 55-64 in the most affluent 
quintile were hospitalised with myocardial infarction (ICD10: I21). 40% of these were 
assumed to be STEMI cases. Uptake of aspirin was estimated to be approximately 
99%. Aspirin use reduces case fatality in patients with ST-segment elevation by 
approximately 23%. The underlying one-year case fatality rate in these men was 
approximately 6%. The DPPs for at least a year were therefore calculated as: 
 
Patient numbers × treatment uptake × relative mortality reduction × one year case 
fatality 
 
= (1,410 × 40%) × 99% × 23% × 6% ≈ 8 DPPs 
 
This calculation was then repeated: 
 
a) For each age-sex-Index of multiple deprivation (IMD) quintile group (70 in total). 
b) Incorporating a Mant and Hicks adjustment8 for multiple medications within each 
patient group (see Section 1.4.1). 
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1.2.4 Risk factor component of IMPACTSEC model 
The second part of the IMPACTSEC model estimated the number of DPPs related to 
changes in cardiovascular risk factor levels in the population. The risk factors 
considered were cigarette smoking, total cholesterol, systolic blood pressure, body 
mass index, diabetes and physical inactivity. The Scottish Health Survey was used to 
calculate trends in the prevalence (or mean values) of each risk factor (Table C). Two 
approaches to calculating DPPs from changes in risk factors were used: the regression 
approach and change in the Population Attributable Risk Fraction (PARF). These are 
illustrated below.  
 
Estimating DPPs from risk factor change – regression approach for continuous risk 
factors 
 
In the regression approach – used for systolic blood pressure (SBP), total cholesterol 
and body mass index – the number of CHD deaths in 2000 (the start year) after 
adjusting for population change between 2000 and 2010 were multiplied by the 
absolute change in risk factor level, and by a regression coefficient (‘beta’) quantifying 
the estimated relative change in CHD mortality that would result from a one-unit 
change in risk factor level (Table I). Natural logarithms were used, as is conventional, 
in order to best describe the log-linear relationship between absolute changes in risk 
factor levels and relative change in mortality. Levels of risk factors in 2000 and 2010 
by sex and SIMD quintile are shown in Table K. 
 
 
EXAMPLE 2: Estimation of DPPs from risk factor changes using regression 
method 
 
Mortality fall due to reduction in SBP in women aged 55-64 in the most affluent quintile 
(in England) 
 
For example, in 2000, there were 227 CHD deaths among 573,291 women aged 55-64 
years in the most affluent quintile in England. The population total had increased to 
714,111 in 2007. Applying the CHD death rate from 2000 (39.6 per 1000) to the 2007 
population gives an (adjusted) total of 283 expected deaths in 2007. 
 
Mean SBP in this group fell by an estimated 4.28 millimetres of mercury (mmHg) (from 
133.8 in 2000 to 129.5 in 2007). The largest meta-analysis reports an estimated age-
sex specific reduction in mortality of 50% for every 20 mmHg reduction in SBP, 
generating a logarithmic coefficient of -0.035 (i.e. natural logarithm of 0.5 divided by 
20). The subsequent reduction in CHD deaths between 2000 and 2007 was then 
estimated as the product of three variables: 
 
DPPs  = expected CHD deaths in 2007 (had 2000 mortality rates remained constant) × 
absolute risk factor reduction between 2000 and 2007 × regression coefficient 
exponentiated 
8 
 
 
DPPs = (1-(exponential (regression coefficient × absolute change))) × expected 
deaths in 2007 
DPPs = (1-(exponential (-0.035 × 4.28))) × 283 ≈ 39 
 
This calculation was then repeated for each age-sex-IMD quintile group. 
 
Data sources for the number of CHD deaths are shown in Table A, the Scottish Health 
Survey (SHeS) was used to estimate risk factor trends (Table C), and sources for the 
regression (beta) coefficients used in these analyses are listed in Table I. The 
regression coefficients were assumed equal across deprivation quintiles. A ‘fixed 
gradient’ approach was used to stabilise estimates of risk factor change across the 
quintiles; this method is discussed in Table O. 
 
Estimating DPPs from risk factor change – PARF approach for binary risk factors 
 
The PARF approach was used for cigarette smoking, diabetes, and physical inactivity. 
PARF, which can be interpreted as the proportion by which the mortality rate from CHD 
would be reduced if the exposure were eliminated,9 was calculated as: 
 
PARF = [P × (RR - 1)] / [1 + P × (RR - 1)] 
 
Where P is the prevalence of the risk factor and RR is the relative risk for CHD 
mortality associated with risk factor presence. A relative risk of 3.3 associated with 
smoking in Scotland, for example, expresses the ratio of risk of CHD mortality in 
smokers to that in non-smokers. DPPs were then estimated as the expected CHD 
deaths in 2010 (had 2000 mortality rates remained constant) multiplied by the 
difference in PARF for 2000 and 2010. 
 
EXAMPLE 3: Estimation of DPPs from risk factor changes using the PARF 
method 
Mortality increase due to increase in diabetes in men aged 65-74 in the most deprived 
quintile (in England) 
 
For example, the prevalence of diabetes among men aged 65-74 years was 7% in 
1998 and 15.7% in 2006. Assuming a relative risk of 1.86, the PARF at the national 
level for men aged 65-74 was 0.057 in 1998 and 0.119 in 2006. 
 
Using estimates of diabetes prevalence pooled over 1998, 2003, and 2006 survey data 
(to maximise precision), and the same relative risk value of 1.86, a ‘risk factor’ 
gradient was calculated using the ratio of the PARF at the national level to that in each 
deprivation quintile (See Table O for details of the SEC gradient approach). The risk 
factor gradient in the PARF in the most deprived quintile was estimated to be 1.38 
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times higher than the national. The gradient of 1.38 was then applied to the national 
PARF values in the base and final year of the model (0.057 and 0.119 respectively) to 
give estimated PARFs of 0.079 (start year) and 0.164 (end year) for men aged 65-74 
in the most deprived quintile. The DPPs attributable to the increase in diabetes 
prevalence was therefore:  
 
DPPs = expected CHD deaths in 2007 (had 2000 mortality rates remained 
constant) × (PARF2000 – PARF2007) 
 
DPPs = expected CHD deaths in 2007 (3,583) × (0.079 – 0.164) ≈ -305 DPPs 
 
A negative sign for the DPPs denotes deaths increased or brought-forward due to the 
increase in diabetes prevalence. The calculation was then repeated for each age-sex-
quintile group. 
 
Relative risks estimated by expert working groups for the World Health Organization’s 
Global Burden of Disease 2001 Study were used for smoking and physical activity.10 
Effect estimates were based on systematic reviews of cohort studies (adjusted for 
regression dilution bias) and meta-analyses of randomised controlled trials. Age-
variation in the relative risks for diabetes were taken from the DECODE study.11 These 
were then applied to the sex-variation in relative risks estimated by Huxley et al.12 The 
published relative risk values for smoking, physical activity and diabetes are shown in 
Table J. These were adjusted in our study to: a) match the 10-year age bands used in 
IMPACTSEC and b) employ a dichotomous rather than trichotomous measure of physical 
activity. Full details on these adjustments are given in Table J. 
 
1.3 CUMULATIVE RISK-REDUCTION: ADJUSTING DEATHS PREVENTED OR 
POSTPONED (DPPs) TO CALCULATE CUMULATIVE BENEFIT OF MULTIPLE RISK 
FACTOR CHANGES 
 
1.3.1 Background 
CHD deaths are usually caused by multiple risk factors acting simultaneously. Hence, 
part of the effect of one risk factor may be mediated through another. For example, 
physical inactivity may have a direct effect on CHD but may also partly be mediated 
through its effects on BMI and blood pressure. It is recommended therefore that 
mortality benefits attributable to risk factors which may be causally related, or which 
overlap in population groups, should not be combined by simple addition. Ideally, their 
effects should instead be jointly estimated.13-17 
 
We do not currently have sources that allow joint estimation of relative risks for 
combinations of risk factors in this Scottish population. However, several large cohort 
studies and meta-analyses have published independent risk reduction coefficients for 
each risk factor included in this study. These are detailed in Tables I and J for 
continuous and dichotomous risk factors, respectively. One approach commonly used is 
to calculate the cumulative risk-reduction.18 This approach accounts for risk factor 
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prevalence overlap but assumes independence of effects.14, 15 The general equation for 
cumulative risk-reduction is stated as: 
 
Combined (or cumulative) effect (CR) =  
 
1 – ((1-a) × (1-b) × (1-c) ×….× (1-n))             [1] 
 
Thus for CHD risk factors, the specific equation is stated as: 
 
CR = 1 – ((1-RSBP) × (1-Rsmoke) × (1-Rdiabetes) ×….× (1-Rn)) 
 
where R denotes the mortality change attributable to a specific risk factor. 
 
This is in contrast to additive risk-reduction (AR): 
 
AR = (RSBP) + (Rsmoke) + (Rdiabetes) +…..+ (Rn)           [2] 
 
 
1.3.2 Implementation 
For the purposes of this modelling study we first calculated the (additive) DPPs 
attributed to risk factor change. These were then adjusted down by using the ratio: 
 
Adjustment factor = CR/AR 
 
The adjustment factor would always be expected to be less than 1. In other words, 
cumulative risk factor reduction would be smaller than the mortality benefits arrived at 
by a simple summation of the benefits of each risk factor in turn.  
 
The proportional change in the CHD mortality rate between two time points (denoted 
by R) was calculated using the following formulas:14, 15 
 
Continuous risk factors: 
 
Rcontinuous  = 1 – exp(beta × absolute mean risk factor change)           [3] 
 
Dichotomous risk factors: 
 
Rdichotomous  = PARF × (∆P/P)                [4] 
 
where PARF = [P × (RR - 1)] / [1 + P × (RR - 1)] 
 
and P denotes prevalence at the start-year; RR the relative risk in CHD mortality 
associated with risk factor presence; and ∆P the change in prevalence between the 
start and final years. 
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Formulas [3] and [4] were used to calculate the proportional change in the CHD 
mortality rate (R) for each risk factor and the steps involved in their estimation are 
detailed below. However, we made two modifications to the methodology used in 
previous work.14, 15 First, we estimated aggregate change over a ten year period 
(2000-2010) rather than average annual change. Second, additive and cumulative 
risk-reduction was calculated by using the absolute values of R (i.e. disregarding the 
direction of risk factor change). These are discussed in turn below. 
 
Calculating aggregate change in risk factors over 2000 and 2010 
 
Previous studies14, 15 estimating cumulative risk factor reduction calculated the average 
annual percentage change in CHD mortality attributable to annual falls in levels of 
smoking, blood pressure and cholesterol (where annual falls in CHD mortality and risk 
factor levels were estimated over a specified number of years). Rather than estimate 
the average annual change over a specific range of years, we were interested in 
calculating the R values between two fixed points in time (start and end years of the 
model), ten years apart, 2000 and 2010. We therefore adapted formulas [3] and [4], 
substituting change over the ten year study period for the estimation of annual 
average change. We checked our resulting estimates of cumulative risk reduction 
calculated over ten years against uprating the annual average by a factor of ten. The 
two sets of estimates were found to be virtually identical. 
 
Regression models to estimate risk factor change, 2000-2010 
 
Formulas [3] and [4] require estimates of absolute and relative change in risk factors, 
respectively. Regression modelling was used to estimate the magnitude of absolute 
and relative change. In order to smooth fluctuations in Scottish Health Survey data, we 
obtained estimates of risk factor change for each risk factor over 2000-2010 by using 
the predicted values from regression models. Separate models were fitted by sex and 
seven ten-year age-bands (14 in total for each risk factor).  
 
Estimates of absolute change in the mean levels of risk factors measured on a 
continuous scale (blood pressure, total cholesterol, and body mass index) were 
calculated by linear regression. The dependent variable was the risk-factor level for 
each survey respondent; calendar year (i.e. year of interview) was the explanatory 
variable entered in the model as a continuous term. Absolute change was measured as 
the difference between the predicted values for 2000 and 2010, by age and sex. 
 
Estimates of change in prevalence estimates (smoking, diabetes and physical activity) 
were calculated using a generalised linear model with binomial distribution and a log 
link function. The outcome variable was binary (1 indicating risk factor presence; 0 
absence) with calendar year as the explanatory variable. The absolute difference in 
predicted values for 2010 and 2000 (∆P in formula [4]) divided by the 2000 value 
provided the estimate of relative change. 
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Estimates of risk factor change were not calculated separately by deprivation quintile 
owing to small sample sizes, especially in those risk factors covered by the survey in 
intermittent years.  
 
Combining risk factors contributing positive and negative benefits to CHD mortality 
change 
 
In previous CHD modelling studies14, 15 adjusting for cumulative risk-reduction was 
straightforward as the trends in smoking, blood pressure and total cholesterol were 
mostly unidirectional: that is, risk factor levels were falling as were CHD mortality 
rates. However, in our current modelling study, mean BMI and the prevalence of 
diabetes increased over 2000-2010 while the four remaining risk factors showed 
favourable trends. In effect, the impact of risk factor change on CHD mortality was not 
uniformly beneficial: therefore, the proportional change in CHD mortality attributable 
to risk factor change was in some cases negative. 
 
In order to avoid positive and negative R values cancelling each other out in the 
mathematical application of cumulative risk-reduction (formula [1] above), with the 
perverse effect of the cumulative benefits being apparently greater than the additive in 
some instances, we first converted all R values into absolute (i.e. sign-free) numbers. 
We did this on the understanding that the proportional change in CHD mortality 
associated with risk factor change was independent of the direction of change. This 
meant that although the R values were not themselves ‘true’ indicators of the total 
proportional reduction in CHD mortality, both the additive and cumulative R values 
were computed on a like-for-like basis. Hence, the ratio of cumulative to additive risk 
reduction (the adjustment factor) was an accurate reflection of the degree to which the 
additive benefits needed to be adjusted down. 
 
Age-sex-SIMD specific adjustment factors (70 in total) were calculated by taking the 
ratio of cumulative to additive risk factor reduction. This involved five steps: 
 
 1. Regression equations were fitted to individual level survey data to derive the 
national predicted risk factor levels for the start and end years of the model. 
Regression models were fitted separately by sex and ten-year age-bands (from 
ages 25 to 85+). (See section above describing the regression models fitted on 
the Scottish Health Survey data to estimate aggregate risk factor change). 
 
 2. The national predicted values for 2000 and 2010 were then graduated for 
increasing deprivation, using the SEC gradient calculated for each risk factor, 
based on pooled Scottish Health Survey data (see Table O). Multiplying the 
national predicted values by the SEC gradient resulted in a set of 70 age-sex-
SIMD specific estimates for 2000 and 2010, for each risk factor.  
 
 3. R values for continuous risk factors were then calculated using estimates of 
absolute change over 2000-2010 (formula [3]). R values for dichotomous risk 
factors were calculated by multiplying the estimated PARF in 2000 by the relative 
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change in prevalence (formula [4]). This resulted in 70 R values (age-sex-SIMD) 
for each risk factor. All R values were then converted into absolute numbers.  
 
 4. The absolute R values were then combined to calculate the additive (AR) and 
cumulative (CR) risk factor reductions (formulas [1] and [2] respectively). Age-
sex-SIMD specific adjustment factors were then calculated using the ratio CR/AR.  
 
 5. Multiplying through the age-sex-SIMD specific additive DPPs in the model for 
each risk factor by the corresponding adjustment factor yielded the estimate of 
the cumulative benefit of risk factor change to CHD mortality decline over the ten 
year period, 2000 and 2010. 
 
Adjustment factors by age-sex-SIMD  
 
The adjustment factors (shown in Table D) fell within the range of 0.85 to 0.93. The 
largest adjustment (0.85) was applied to the DPPs for those resident in the most 
deprived areas (men aged 55-64 and women aged 45-74 in SIMD5). The adjustments 
were on average, the same for women and men (0.89); and were higher in IMDQ5 
than in IMDQ1 (mean values 0.88 and 0.91, respectively). Hence the adjustment 
values indicated a larger downward adjustment to the additive DPPs in the most 
deprived areas relative to the most affluent. 
 
1.4 Other methodological considerations 
Other than calculations to take into account change in treatments and risk factors over 
time, several other adjustments had to be made.  These include: 
 adjusting the relative reduction in the case fatality rate for persons 
receiving multiple treatments (poly-pharmacy),  
 establishing rules for avoiding double-counting individuals belonging to 
more than one patient group,  
 Assigning emergency AMI patients to either STEMI or nSTEMI patient 
groups, 
 Assigning PCI uptake to either STEMI or nSTEMI, 
 overlap between pharmacological and non-pharmacological contribution 
to risk factor change,  
 uncertainty analyses,  
 measuring net effects of changes in treatment uptake, 
 allocating areas to quintiles by socioeconomic circumstances. 
 
These are discussed in turn below. 
 
1.4.1 Accounting for poly-pharmacy  
Persons with or at high risk of developing CHD may take a number of different 
medications. However, data from randomised clinical trials on efficacy of treatment 
combinations are sparse. Mant and Hicks suggested a method to estimate case fatality 
reduction by poly-pharmacy.8 The adjustment is carried out in a step-by-step manner 
14 
 
as set out in the example below. First the total effect is calculated using an 
inappropriate additive model, which is then adjusted using effect size calculation with 
an appropriate multiplicative model. 
 
Example 4: Estimation of reduced benefit if patient taking multiple 
medications (Mant and Hicks approach) 
 
Adjustment for polypharmacy in secondary prevention post myocardial infarction in 
men aged 55-64 in the most affluent quintile (in England) 
 
Taking the example of secondary prevention post myocardial infarction, good evidence 
(Table F) suggests that, for each intervention, the relative reduction in case fatality is 
approximately: aspirin 15%, beta-blockers 23%, ACE inhibitors (ACE I) 20%, statins 
22%, warfarin 22%, and rehabilitation 26%. Our best estimates for uptake were 
respectively 69%, 59%, 68%, 83%, 3%, and 45%. Assuming a one-year case fatality 
rate of 0.013 for men aged 55-64 and a total of 15,068 men aged 55-64 residing in 
the most affluent quintile in 2007 the total DPPs, with no adjustment for poly-
pharmacy, would be calculated as shown in the table below: 
 
Secondary 
prevention 
post MI 
 
Numbers 
 
Treatment 
uptake 
 
Comp-
liance 
Relative 
risk 
reduction 
One year 
case 
fatality 
 
Unadjusted 
DPPs 
 
Treatment A B C D E (A × B × C 
× D × E) 
Aspirin 15,068 0.69 70% 0.15 0.013 14 
Beta blockers 15,068 0.59 70% 0.23 0.013 19 
ACE Inhibitors 15,068 0.68 70% 0.20 0.013 19 
Statins 15,068 0.83 50% 0.22 0.013 18 
Warfarin 15,068 0.03 70% 0.22 0.013 1 
Rehabilitation 15,068 0.45 65% 0.26 0.013 15 
Total      85 
 
The Mant and Hicks approach suggests that in individual patients receiving all these 
interventions, case fatality reduction is very unlikely to be simply additive. Instead, 
having considered the 15% case fatality reduction achieved by aspirin, the next 
medication, in this case a beta-blocker, can only reduce the residual case fatality (1-
15%). Likewise, the subsequent addition of an ACE inhibitor can then only decrease 
the remaining case fatality, which will be 1 – [(1-0.15) × (1-0.23)]. The Mant and 
Hicks approach therefore suggests that a cumulative relative benefit can be estimated 
as follows: 
 
Cumulative relative benefit = 1 – [(1 – (uptake of drug A × relative reduction in case 
fatality rate for drug A)) × (1 – (uptake of drug B × relative reduction in case fatality 
rate for drug B)) × …. × (1 – (uptake of drug N × relative reduction in case fatality 
rate for drug N))] 
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In considering appropriate treatments for post MI patients, applying relative risk 
reductions (RRR) for aspirin, beta-blockers, ACE I, statins, warfarin, and rehabilitation 
then gives the following cumulative relative benefit (using a weighted average of the 
age-sex specific uptake figures in each quintile): 
 
=1 – [(1 – (aspirinuptake × aspirinRRR)) × (1 – (beta blockersuptake × beta blockersRRR)) × 
(1 – (ACE Iuptake × ACE IRRR)) × (1 – (statinsuptake × statinsRRR)) × (1 – (warfarinuptake × 
warfarinRRR)) × (1 – (rehabilitationuptake × rehabilitationRRR)) 
 
= 1 – [(1 – (0.72 × 0.15)) × (1 – (0.54 × 0.23)) × (1 – (0.63 × 0.20)) × (1 – (0.78 × 
0.22)) × (1 – (0.08 × 0.22)) × (1 – (0.45 × 0.26))] 
= 1 – [(0.89) × (0.88) × (0.87) × (0.81) × (0.98) × (0.88)] 
≈ 0.52 (i.e. a 52% lower case fatality) 
 
This represented a 24% relative reduction 1-(0.52/0.68) on the simple additive value 
of 68%, resulting in 24% fewer DPPs out of an original total of 85 DPPs (leaving an 
adjusted total of 65): 
 
Adjusted DPPs = unadjusted DPPs × (cumulative relative benefit / additive 
benefit) 
 Adjusted DPPs = 85 × (0.52/0.68) ≈ 65 
 
All treatment DPPs quoted in the results tables refer to the adjusted DPPs. 
 
 
1.4.2 Potential overlaps between patient groups: avoiding double counting 
There are potential overlaps between CHD patient groups. For example, approximately 
30% of myocardial infarction survivors have or will go on to develop heart failure 
within 12 months. Overlap adjustments between CHD patient groups were made to 
ensure that the final groups could be considered mutually exclusive. Patient overlaps 
for 2010 are shown in Figure N.1. 
 
1.4.3 Assigning emergency AMI patients to either STEMI or NSTEMI patient 
groups 
 
Specific data was not available to distinguish emergency AMI admissions as either 
STEMI or NSTEMI cases. In the previous use of the IMPACTSEC model in England1 the 
assumption had been made that 40% of emergency AMI admission would be STEMI 
and 60% NSTEMI. This assumption was also used in relation to emergency AMI 
admissions during 2000 in this Scottish IMPACTSEC model. 
 
For 2010 data it was possible to make a more informed assumption as to the ratio of 
STEMI/nSTEMI cases using SMR01 data for the year 2011. New rules introduced by 
ISD for coding SMR data came in to affect from October 2010. In brief it was dictated 
that:  
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1. Unstable angina should be coded as I20.0 (Unstable angina), exactly according 
to ICD10 rules and conventions. 
2. ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial 
infarction (NSTEMI) should be coded using the existing structure of the ICD10 
codes for MI by adding a 5th digit for use only with codes I21 (Acute myocardial 
infarction) and I22 (Subsequent myocardial infarction). This is summarised in 
the table below: 
 
Fifth digit Meaning of fifth digit for I21.- and I22.- ONLY  
0  NSTEMI 
1  STEMI 
9  MI with no statement of ST elevation or non-elevation  
 
All emergency AMI index events for the year 2011 (ICD code I21) were identified using 
the same rules as for 2010. In the table below the breakdown in emergency AMI 
according to the revised coding for the year 2011 is detailed below. Not all coders were 
using the new coding system. However, the ratio of STEMI/NSTEMI could be 
estimated; overall the proportion of AMI admissions coded as STEMI= 35%. 
 
Fifth digit coding for 2011 emergency AMI admissions 
Total emergency 
AMI 
No 
fifth 
digit MI_ND NSTEMI STEMI 
STEMI 
plus 
NSTEMI 
STEMI 
proportion 
7497 2009 596 3158 1734 4892 0.35 
 
The table below details age group and gender specific proportions of STEMI/NSTEMI 
patients estimated for 2011. These were then applied to the corresponding emergency 
AMI groups for 2010 to apportion the divide in cases. 
 
Using just the AMIs coded for STEMI and NSTEMI to give age/gender splits for 
STEMI/NSTEMI in 2010 combine this with emergency AMIs 
 
 Number of NSTEMI 
and STEMI (n) 
Proportion 
NSTEMI 
Proportion 
STEMI 
    
All 4892 0.65 0.35 
Men 3012 0.62 0.38 
Women 1879 0.68 0.32 
    
M25-34 18 0.06 0.94 
M35-44 162 0.53 0.47 
M45-54 561 0.51 0.49 
M55-64 788 0.56 0.44 
M65-74 678 0.68 0.32 
M75-84 601 0.72 0.28 
M85+ 204 0.81 0.19 
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W25-34 4 0.50 0.50 
W35-44 47 0.51 0.49 
W45-54 177 0.63 0.37 
W55-64 283 0.59 0.41 
W65-74 430 0.66 0.34 
W75-84 569 0.72 0.28 
W85+ 370 0.76 0.24 
 
1.4.4 Assigning PCI uptake to either STEMI or NSTEMI 
 
In the previous use of the IMPACTSEC model in England1 the assumption was made that 
the uptake of PCI for AMI was exclusively for STEMI cases. The uptake of PCI for UA 
was also used as a proxy for the combined uptake of PCI by UA and nSTEMI cases 
(nSTEACS). This assumption was utilised for 2000 data in this Scottish IMPACTSEC 
model. 
 
For the 2010 data it was decided that this assumption was no longer appropriate. By 
2010 the use of PCI had increased dramatically in Scotland and is the treatment of 
choice (where appropriate) for all AMI cases (not just STEMI cases). SMR01 data for 
2011 was used to estimate the proportional uptake of PCI by STEMI and NSTEMI cases 
to guide the apportioning of the PCI uptake by each disease group in 2010. This data 
was stratified by age group and gender. 
 
Table below shows those coded as STEMI and NSTEMI 2011 the proportion with PCI: 
 
 NSTEMI
/STEMI 
NSTEMI STEMI PCI 
NSTEMI
/STEMI 
PCI 
NSTEMI 
PCI 
STEMI 
       
All 4892 0.65 0.35 1288 0.16 0.84 
Men 3012 0.62 0.38 923 0.17 0.83 
Women 1879 0.68 0.32 365 0.14 0.86 
       
M25-34 18 0.06 0.94 12 0.00 1.00 
M35-44 162 0.53 0.47 75 0.19 0.81 
M45-54 561 0.51 0.49 245 0.14 0.86 
M55-64 788 0.56 0.44 290 0.16 0.84 
M65-74 678 0.68 0.32 168 0.21 0.79 
M75-84 601 0.72 0.28 118 0.18 0.82 
M85+ 204 0.81 0.19 15 0.13 0.87 
W25-34 4 0.50 0.50 2 0.50 0.50 
W35-44 47 0.51 0.49 16 0.06 0.94 
W45-54 177 0.63 0.37 57 0.21 0.79 
W55-64 283 0.59 0.41 82 0.09 0.91 
W65-74 430 0.66 0.34 98 0.12 0.88 
W75-84 569 0.72 0.28 89 0.18 0.82 
W85+ 370 0.76 0.24 21 0.10 0.90 
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1.4.5 Overlap between pharmacological and non-pharmacological 
contributions to risk factor DPPs 
Risk factor improvements, such as lower blood pressure or total cholesterol, may be 
achieved through medications, lifestyle changes, or a combination. In order to 
separate the DPPs from pharmacological versus non-pharmacological contributions to 
CHD mortality, we subtracted the DPPs calculated in the treatment (primary 
prevention) component of the model from the DPPs calculated in the risk factor 
component. That is, to estimate the impact of population-wide reduction in total 
cholesterol due to non-pharmacological change, we subtracted the estimated effect of 
statins for the primary prevention of CHD from the overall number of DPPs due to 
change in mean total cholesterol. Similarly, to estimate the impact of the population-
wide reduction in SBP we subtracted the estimated effect of anti-hypertensive 
medication for primary prevention from the overall number of DPPs due to change in 
mean SBP levels.  
 
1.4.6 Net effects 
As all treatments were in use in 2000, the net benefit of an intervention in 2010 was 
calculated by subtracting the expected number of deaths prevented if the uptake rates 
in 2000 remained constant from the estimated number of deaths prevented calculated 
using the 2010 uptake rates. This is illustrated in the example below. 
 
EXAMPLE 5: Net effects for treatments 
Calculating net effects for clopidogrel use in STEMI cases in men aged 75-84 in the 
most affluent quintile (in England) 
 
With an estimated total of 1,440 men aged 75-84 in the most affluent quintile (of 
whom 40% were assumed to be STEMI cases), 89% uptake, a relative risk reduction of 
3%, a one-year case fatality rate of 34%, and 100% compliance, the total number of 
DPPs in 2007 was calculated as: 
 
Patient numbers × treatment uptake2007 × relative mortality reduction × one 
year case fatality 
 
= (1,440 × 40%) × 89% × 3% × 34% ≈ 5 DPPs 
 
Applying the uptake rate in 2000 (31%) gave a total of 2 DPPs: 
 
Patient numbers × treatment uptake2000 × relative mortality reduction × one 
year case fatality 
 
= (1440 × 40%) × 31% × 3% × 34% ≈ 2 DPPs 
 
The net DPPs were therefore: 
 
Net DPPs = DPPs using uptake2007 – DPPs using uptake2000  
= 5 –2 = 3 
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The estimated changes in treatment uptake between 2000 and 2010 by deprivation 
quintile are shown in Table H.    
 
In a small number of cases, “negative” DPPs were apparently generated reflecting a 
decrease in treatment uptake or numbers. For instance with CPR in hospital (fewer 
number of arrests requiring resuscitation) and thrombolysis treatments (a larger 
proportion receiving angioplasty instead of thrombolysis). These negatives were mostly 
trivial, and were zeroed to reflect the reality: harmful treatments were not being 
administered. This approach was applied only to disease group (DG) 1 (STEMI) in 
relation to in-hospital CPR and treatment using thrombolysis and disease group 2 
(NSTEACS) in relation to in-hospital CPR and treatment using aspirin but no heparin. 
The effects of zeroing the negatives on the DPPs for DG1 and DG2 are illustrated in the 
tables below. It was considered unnecessary to correct the very minor negative DPPs 
associated with three treatments in the DG4 and DG5 community groups. 
 
Original DPPs for disease groups one and two before zeroing of negative DPPS for 
selected treatments 
 NET DPPs  SIMDQ1 SIMDQ2 SIMDQ3 SIMDQ4 SIMDQ5 
INITIAL TREATMENTS FOR ACUTE MI (DG1) - STEMI    
Community CPR 2 0 1 0 1 1 
Hospital CPR (STEMI) -27 -3 -4 -6 -7 -7 
Thrombolysis -27 -4 -4 -5 -6 -7 
Aspirin 4 1 1 1 1 1 
Beta blockers 0 0 0 0 0 0 
ACE inhibitors/ARB 0 0 0 0 0 0 
PPCI 90 16 18 18 19 19 
CABG 0 0 0 0 0 0 
Clopidogrel 12 2 2 2 3 2 
Sum (2010) 54 12 12 9 11 10 
       
NSTEACS (DG2)       
Hospital CPR (NSTEMI) -37 -5 -7 -8 -9 -9 
Aspirin & heparin 40 5 8 7 8 11 
Aspirin alone (without heparin) -13 -1 -3 -2 -3 -4 
PG IIA/IIIB 0 0 0 0 0 0 
CABG surgery (within 7 days) 0 0 0 0 0 0 
PTCA (within 7 days) 7 1 2 1 1 2 
ACE inhibitors/ARB 5 1 1 1 1 1 
Beta blockers 3 0 1 1 1 1 
Clopidogrel 23 4 5 5 5 5 
Sum (2010) 27 4 6 5 5 7 
Treatments affected by zeroing of negative DPPS are shaded in grey 
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DPPs for disease groups one and two after zeroing of negative DPPS for selected 
treatments 
 NET DPPs  SIMDQ1 SIMDQ2 SIMDQ3 SIMDQ4 SIMDQ5 
INITIAL TREATMENTS FOR ACUTE MI (DG1) - STEMI    
Community CPR 2 0 1 0 1 1 
Hospital CPR (STEMI) 0 0 0 0 0 0 
Thrombolysis 0 0 0 0 0 0 
Aspirin 4 1 1 1 1 1 
Beta blockers 0 0 0 0 0 0 
ACE inhibitors/ARB 0 0 0 0 0 0 
PPCI 90 16 18 18 19 19 
CABG 0 0 0 0 0 0 
Clopidogrel 12 2 2 2 3 2 
Sum (2010) 108 19 21 21 23 24 
       
NSTEACS (DG2)       
Hospital CPR (NSTEMI) 0 0 0 0 0 0 
Aspirin & heparin 40 5 8 7 8 11 
Aspirin alone (without heparin) 0 0 0 0 0 0 
PG IIA/IIIB 0 0 0 0 0 0 
CABG surgery (within 7 days) 0 0 0 0 0 0 
PTCA (within 7 days) 7 1 2 1 1 2 
ACE inhibitors/ARB 5 1 1 1 1 1 
Beta blockers 3 0 1 1 1 1 
Clopidogrel 23 4 5 5 5 5 
Sum (2010) 78 10 16 15 17 20 
Treatments affected by zeroing of negative DPPS are shaded in grey 
 
1.4.7 Uncertainty analyses 
We implemented uncertainty analysis in Excel using Ersatz (version 1.0 available at 
http://www.epigear.com).  This is an add-on which allows probabilistic bootstrapping 
in Excel. Ersatz allows repeated random draws from specified distributions for input 
variables and then calculates the 95% uncertainty intervals from the realised values of 
the output variable (deaths prevented or postponed). For the IMPACTSEC model, we 
calculated the uncertainty intervals based on 1000 draws – taking the 95% uncertainty 
intervals from the 2.5th and 97.5th percentiles. The parameter distributions used for 
the input variables to the DPP calculations are shown in Table M. Worked examples 
using Ersatz are shown below Table M.   
 
1.4.8 Model fit 
Overall, the model could not explain 19% of the total deaths prevented (i.e. a shortfall 
of about 1000 CHD deaths unexplained by the model). However, the percentage 
unexplained varied by age, sex and socio-economic circumstances. These are shown in 
Tables L.1- L.4 and Figure L.1. 
 
1.4.9 Allocating areas to socioeconomic quintiles using Scottish Index of 
Multiple Deprivation, 2009 
The Scottish Index of Multiple Deprivation (SIMD) identifies small area concentrations 
of multiple deprivation across all of Scotland and is based on seven domains, income; 
employment; health; education, skills and training; housing; geographical access to 
services; and crime. The overall SIMD 2009v2 utilises data based principally on 2008 
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with population data from 2007 19. The SIMD is presented at data zone level, enabling 
small pockets of deprivation to be identified. The data zones, which have a median 
population size of 769, are ranked from most deprived (1) to least deprived (6,505). 
The datazones were grouped into equal quintiles representing 20% of the population 
with quintile one (SIMDQ1) including the most affluent and quintile five (SIMDQ5) the 
most deprived areas. The result is a comprehensive picture of relative area deprivation 
across Scotland. SIMD is essentially identical / very similar to Index of multiple 
deprivation (IMD) successfully used in the English IMPACTSEC project.1 Based on their 
postcode of residence, patients treated in hospital (e.g. SMR01) or in the community 
(e.g. PCCIUR) were matched via their area of residence to the corresponding 
deprivation quintile by the data providers to protect patient anonymity. The PCCIUR 
dataset does not have individual level SIMD information available therefore quintiles of 
individual 2001 Carstairs index were substituted.20 SIMD quintiles were assigned to 
population and mortality data using look-up files based on datazone. Similarly 
anonymous look-up files for SIMD quintiles were provided by Scotcen21 to enable 
assignment of SIMD quintiles to the Scottish Heath Survey datasets obtained from the 
University of Essex Research Repository. It was not possible to obtain information 
stratified by any measure of deprivation for the following datasets: 2008 Health 
Improvement Scotland Heart Failure audit and the 2010/2011 Health Improvement 
Scotland Cardiac Rehabilitation Audit. 
 
The health domain of SIMD includes an indicator of the Comparative Mortality Factor 
(CMF) and so includes number of deaths in the period under examination. Describing 
deprivation by a measure that includes this domain may be thought of as tautological 
since the outcome we are analysing is CHD deaths. However UK studies have shown 
that removing the health domain had little effect on either the assignment of areas into 
their deprivation quintile or the relationship between area-based deprivation and 
health.22 Conceptually, the SIMD is a measure of deprivation, not a measure of 
affluence. Hence, areas with the lowest scores are not necessarily the most affluent; 
rather they have the lowest concentration of deprived people. In this paper for clarity 
and to easily distinguish between the extreme ends of the deprivation spectrum, we 
have used the term ‘most affluent’ and ‘most deprived’ rather than ‘least deprived’ and 
‘most deprived’. 
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Table A. Population and patient data sources used in the 
IMPACTSEC model 
 Data by gender age and SIMD quintile unless stated  
 
 
Information Source 
 
Population data 
Population: 
  counts by age, sex and SIMD 
 
National Records of Scotland (NRS)  
 
(2000  and 2010: ICD10 I20-I25) 
 
Deaths: 
  counts by age, sex and SIMD 
 
Number of patients admitted to hospital 
Myocardial infarction (MI) 
  STEMI 
  nSTEMI 
Information Services Division (ISD) – linked SMR01b and 
death record dataset  
Emergency admissions with a primary diagnosis of MI 
(ICD10: I21) 
2000: the ratio of MI admissions to STEMI and nSTEMI 
cases taken as 40/6023 
2010: the age-gender specific ratios of STEMI to NSTEMI 
in 2011 were used to inform the split (see section 1.4.8) 
 
Angina pectoris 
 
ISD - linked SMR01b and death record dataset Emergency 
admissions with a primary diagnosis of angina pectoris 
(ICD10: I20)  
 
Heart failure  
  (non CHD excluded) 
 
ISD - linked SMR01b and death record dataset Admissions 
with a primary diagnosis of heart failure (ICD10: I50); 
restrict to those with heart failure due to CHD (coded in 
prior record, or as a co-morbidity (ICD-10 I20-I25)) 
 
Number of patients undergoing revascularisation 
CABG ISD - linked SMR01 and death record dataset 
OPCS Classification of Surgical Operations and Procedures 
(4th Revision) (OPCS-4) K40-K46 and (OPCS-3) 3043 
 
PCI 
 
ISD - linked SMR01 and death record dataset 
OPCS Classification of Surgical Operations and Procedures 
– Fourth Revision (OPCS-4) OPCS K49, K50.1, K508.8,  
K75 (No OPCS-3) 
 
Patients in the community eligible for secondary prevention therapies 
Post MI (eligible for cardiac 
rehabilitation) 
 
Angina without MIa 
 
Heart failurea 
 
ISD - Linked SMR01c and death record dataset 
 
 
Primary Care Clinical Informatics Unit (PCCIUR) 
 
Primary Care Clinical Informatics Unit (PCCIUR) 
 
CABG/PCI survivors (eligible for 
cardiac rehabilitation) 
ISD - Linked SMR01c and death record dataset 
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Patients eligible for primary prevention therapies 
Lipid-lowering drugs 
Prevalence of never having had 
angina or heart attack and 
currently taking lipid lowering drugs 
prescribed by a doctor 
 
Scottish Health Survey 
1998, 2003, 2010 (2008, 2009 and 2010 combined) 
 
Hypertension treatment 
Prevalence of never having had 
angina or heart attack and 
currently taking medication 
specifically prescribed to treat high 
blood pressure 
 
Scottish Health Survey 
1998, 2003, 2010 (2008, 2009 and 2010 combined) 
 
a Individual Carstairs scores20 used to assign deprivation quintiles in 2000 and 2010 as 
SIMD unavailable 
b SMR01 linked dataset extracted in March 2013 
c	Data only available for 2004-2010 
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Table B. Data sources for treatment uptake levels 
 Medical treatments included in the model. All data stratified by gender, 
age group and SIMD quintile unless stated. 
 
Information Source 
 
Medication use in hospital (ST-segment elevation myocardial infarction) 
 Aspirin 
 Beta Blockers 
 ACE I or Angiotensin-II receptor 
 antagonists (ARB) 
 Thrombolysis 
 Clopidogrel 
 
MINAP 2003 to 2007a  
Non-ST-segment elevation acute coronary syndrome (NSTEACS) 
 Aspirin without heparin 
 Aspirin & heparin 
 Platelet glycoprotein IIB/IIIA 
 inhibitors 
 Beta Blockers 
 ACE I/ARB 
 Clopidogrel 
 
MINAP 2003 to 2007a 
Heart failure due to CHD 
 Aspirinb 
 Beta blockers 
 ACE I/ARB 
 Spironolactone 
Health Improvement Scotland Audit HFb 
 
 
In-hospital cardio-pulmonary resuscitation (CPR)  
 MINAP 2003 to 2007 
 
CPR in the community  
 HeartStart (Scotland) Register annual data 2000 to 
2007 
 
Cardiac rehabilitation for MI & revascularisation survivors (2006-2010 survivors only) 
 2010-2011 (financial year): Health Improvementc 
Scotland Audit CR (ISD website)  
2000: not availabled 
Estimates are for completion of rehabilitation 
program  
 
Medication use in the community: Post MI and revascularisation survivors, chronic 
stable coronary artery disease (CAD), heart failure  
  Aspirin 
  Beta blockers 
  ACE I/ARB 
  Statins  
  Warfarin 
  Spironolactone 
 
Primary Care Clinical Informatics Unit (PCCIUR)e 
 
Primary prevention therapies: 
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Lipid-lowering drugs  
Prevalence of never having had angina or 
heart attack and currently taking lipid 
lowering drugs prescribed by a doctor 
 
Scottish Health Survey 
1998, 2003, 2010 (2008, 2009 and 2010 combined) 
 
Anti-hypertensive medication  
Hypertension treatment  
Prevalence of never having had angina or 
heart attack and currently taking 
medication specifically prescribed to treat 
high blood pressure 
 
Scottish Health Survey 
1998, 2003, 2010 (2008, 2009 and 2010 combined) 
 
a Data stratified by IMD, age and sex (English data) 
bAssumed equal to HF with CHD rates in the community obtained from PCCIUR 
c Data not stratified by deprivation quintile 
d Estimate not available so based on ratio approach and literature  
e Individual Carstairs scores20 used to assign deprivation quintiles in 2000 as SIMD 
unavailable 
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Table C. Risk factors – variable definitions and source 
 
The Scottish Health Survey (SHeS) is a cross-sectional, nationally representative 
survey reporting the health and health-related behaviours (with emphasis on 
cardiovascular disease) of people living in private households in Scotland.24 Surveys 
have been conducted in 1995, 1998, 2003 and since 2008 they have been repeated 
yearly as part of a continuous survey until 2012. Samples are selected using a multi-
stage stratified clustered probability sampling design. Data are collected during two 
household visits; first by an interviewer (face-to-face interviews) then by a nurse.  
 
During the face-to-face interviews current cigarette smoking status, physical activity 
behaviour and self-reported diabetes are ascertained. Compliance to the physical 
activity recommendations ≥5 occasions/week of at least moderate activity (for a total 
of at least thirty minutes per day) is recorded. Contributing activities included those 
performed at home (housework, gardening, DIY etc) and at work, as well as sport, 
exercise and walking. Activities performed for longer than fifteen minutes contributed 
to the total. Self-reported diabetes is recorded only if a doctor had informed 
respondents of the diagnosis. This was irrespective of treatment and was excluded if 
associated with pregnancy (no blood samples were taken for glucose in the SHeS). The 
interviewers also obtained weight and height measurements. Bodyweight is measured 
to the nearest 100g using electronic scales, an estimate is requested from respondents 
that exceeded the scales’ upper limit of 130kg. Height is measured to the nearest 
millimetre using a stadiometer. 
 
During the nurse visit blood pressure measurements, details of prescription drug use 
for hypertension, details of lipid lowering drugs and non-fasting venous blood samples 
were taken. Blood pressure readings were taken three times using an automated 
device with the informant in a seated position, after a five-minute rest. Readings were 
taken from participants that had not eaten, smoked, drunk alcohol or taken vigorous 
exercise in the 30 minutes preceding measurement. The 1995 and 1998 surveys 
employed Dinamap 8100 monitors (Critikon, USA) while from 2003 Omron HEM 907 
devices (Omron Healthcare, Japan) were used. Regression equations generated from 
a calibration study are available to derive predicted Omron readings from Dinamap 
readings. The same laboratory conducted all blood sample analyses (except 1995). 
Total cholesterol serum concentration was determined by a cholesterol oxidase assay. 
 
We used all available surveys from 1998 to 2010 within gender stratified generalised 
linear models to produce point estimates for both 2000 and 2010 for the six risk 
factors. The 1995 survey was not used due to missing or non compatible variables, a 
more limited age range plus the time period focused on is 2000 to 2010 – 1995 is 
outside this and should not be allowed to have undue influence.  
 
For the categorical risk factors (smoking, diabetes and physical activity) a generalised 
linear model with binomial distribution and a logit link function was employed. The 
outcome variable was binary (1 indicating risk factor presence; 0 absence) with 
calendar year and age group (10 year bands) as explanatory variables. Interaction 
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between year and age group were investigated as well as transformations of year (e.g. 
quadratic term for year). In the case of physical activity amongst women there was a 
significant interaction between year and age group and this was included in the 
prediction model. For the continuous risk factors (BMI, SBP and cholesterol) a 
generalised linear model with normal distribution and an identity link function was 
utilised. The dependent variable was the risk-factor level for each survey respondent; 
calendar year (i.e. year of survey) and age group (10 year bands) were the 
explanatory variables. There were significant interactions between age and year for all 
genders and risk factors so this was included in the model. Additionally for cholesterol 
a quadratic term for calendar year significantly improved the model for both genders 
and this was also included in the model.  
 
The magnitude of risk factor change from 2000 to 2010 used for the calculation of 
DPPs (see Examples 2 and 3) was estimated using a ‘fixed gradient’ approach across 
deprivation quintiles to maximise precision. All surveys were pooled to enable 
stratification by age, sex and SIMD quintile (70 groups) to obtain the fixed 
socioeconomic gradient; for details on this approach see Table O. 
 
SHeS data was accessed from the Essex archive. Anonymous look up files for SIMD 
quintiles were provided by Scotcen. 
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Risk factor SHeS survey 
years 
 
Description 
Current cigarette 
smoking 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
Self-reported status 
SBP (mmHg) 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
Mean of second and third readings of 
participants that had not eaten, smoked, 
drunk alcohol or taken vigorous exercise 
in the 30mins preceding measurement. 
 
Body Mass Index 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
Valid height and weight measurements 
 
Total cholesterol 
(mmol/l) 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
Those reporting taking lipid lowering 
drugs were included 
 
Diabetes 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
If a doctor had informed respondents of 
the diagnosis, irrespective of treatment 
and was excluded if associated with 
pregnancy. 
 
Physical inactivity 
 
1998, 2003, 
(2008, 2009, 
2010)a  
 
≥5 occasions/week of at least moderate 
activity (for a total of at least 30mins per 
day). Contributing activities included 
those performed at home (housework, 
gardening, DIY etc) and at work, as well 
as sport, exercise and walking. Activities 
performed for longer than fifteen 
minutes contributed to the total. 
 
 
a 2008, 2009 and 2010 combined 
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Table D. Cumulative benefit: Adjustment factors by age, sex and 
SIMD quintile 
 The DPPs were adjusted down in an additive fashion over the six risk 
factors by using the ratio of cumulative to additive risk-reduction (section 
1.3). The 70 age-sex-SIMD specific adjustment factors are shown below. 
 
 Deprivation quintile  
 SIMDQ1 SIMDQ2 SIMDQ3 SIMDQ4 SIMDQ5 Scotland 
Men:       
25-34 0.8775 0.8793 0.8604 0.8700 0.8691 0.8703 
35-44 0.8845 0.8809 0.8766 0.8626 0.8748 0.8749 
45-54 0.9171 0.9064 0.8993 0.8984 0.8877 0.9010 
55-64 0.8902 0.8751 0.8688 0.8664 0.8542 0.8702 
65-74 0.9098 0.9039 0.8992 0.8906 0.8887 0.8982 
75-84 0.8902 0.8828 0.8865 0.8846 0.8764 0.8847 
85+ 0.9227 0.8974 0.9033 0.9209 0.9057 0.9094 
Women:       
25-34 0.9077 0.9034 0.9028 0.8868 0.8877 0.8960 
35-44 0.9323 0.9232 0.9085 0.9127 0.8990 0.9140 
45-54 0.8958 0.8880 0.8663 0.8626 0.8535 0.8715 
55-64 0.8950 0.8901 0.8716 0.8715 0.8543 0.8751 
65-74 0.8773 0.8751 0.8630 0.8571 0.8493 0.8634 
75-84 0.8869 0.8855 0.8866 0.8750 0.8678 0.8802 
85+ 0.9316 0.9329 0.9205 0.9215 0.9139 0.9233 
Overall 0.9013 0.8946 0.8867 0.8843 0.8773 0.8749 
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Table E. CHD mortality rates 2000 and 2010 by sex and 
deprivation quintiles 
 
 Year Scotland SIMD 
Q1 
SIMD 
Q2 
SIMD 
Q3 
SIMD 
Q4 
SIMD 
Q5 
Male        
Population  2000 1645868 326354 322654 333889 336500 326471 
 2010 1745130 352118 364751 361232 346602 320427 
Observed CHD deaths 2000 6464 799 1013 1356 1519 1777 
 2010 4529 623 785 909 1079 1133 
Age-standardised 
rates (per 100,000)a 
2000 363 252 293 364 393 494 
2010 210 139 169 197 253 313 
Annual % fallb  5.3 5.8 5.4 5.9 4.3 4.5 
Expected deathsc 2010 7603 1119 1348 1653 1684 1799 
Target DPPsd 2010 3074 496 563 744 605 666 
% of expected 
deaths prevented 2010 40.4 44.3 41.8 45.0 35.9 37.0 
Female        
Population  2000 1870132 358808 355786 371914 390437 393187 
 2010 1940414 383671 396873 394327 390188 375355 
Observed CHD deaths 2000 5796 754 952 1207 1408 1475 
 2010 3513 514 632 670 841 856 
Age-standardised 
rates (per 100,000)a 
2000 185 129 155 186 201 239 
 2010 99 69 81 91 118 141 
Annual % fallb  6.0 6.0 6.3 6.9 5.2 5.1 
Expected deathsc 2010 6210 923 1128 1317 1423 1419 
Target DPPsd 2010 2697 409 496 647 582 563 
% of expected 
deaths prevented 2010 43.4 44.3 44.0 49.1 40.9 39.7 
Total        
Population  2000 3516000 685162 678440 705803 726937 719658 
 2010 3685544 735789 761624 755559 736790 695782 
Observed CHD deaths 2000 12260 1553 1965 2563 2927 3252 
 2010 8042 1137 1417 1579 1920 1989 
Age-standardised 
rates (per 100,000)a 
2000 262 181 215 263 283 349 
 2010 148 100 120 137 177 217 
Annual % fallb  5.5 5.8 5.7 6.3 4.6 4.6 
Expected deathsc 2010 13813 2042 2476 2971 3107 3218 
Total DPPsd 2010 5771 905 1059 1392 1187 1229 
% of expected 
deaths prevented 2010 
41.8 44.3 42.8 46.9 38.2 38.2 
a Rates are standardised to the European Standard Population aged 25+ years 
b Annual % fall = (1-(2010 rate/2000 rate)^(1/10)) 
c Expected deaths = CHD deaths expected in 2010 had 2000 CHD rates remained.  
d DPPs, deaths prevented or postponed. DPPs = expected – observed deaths in 2010 
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Table F. Clinical efficacy of interventions: relative risk reductions 
obtained from meta-analyses, and randomised clinical 
trials 
 
Treatments Relative 
risk 
reductiona 
Comments Source paper: First 
author (year) [ref 
list], notes 
ST elevation myocardial infarction (STEMI): 
 
    
Thrombolysis 31%  
(95% CI: 14,45) 
<55 years: Odds Ratio 
(OR)=0.692; Relative Risk 
Reduction (RRR)=30.8% (95% 
CI: 14,45) 
55-64 years: OR=0.736; 
RRR=26.4% (95% CI: 17,40) 
65-74 years: OR=0.752; 
RRR=24.8% (95% CI: 15,37) 
> 75 years: OR=0.844; 
RRR=15.6% (95% CI: 4,30) 
 
Estess (2002)25 
Aspirin 23%  
(95% CI: 15,30) 
 
RRR=23% (95% CI: 15,30): 
outcome is vascular deaths 
 
ISIS-2 (1988)26 
Primary CABG 
surgery 
39%  
(95% CI: 23,52) 
OR=0.61 (95% CI: 0.48,0.77); 
RRR=39% (95% CI: 23,52) on 
page 565, 0-5 year mortality 
 
Yusuf (1994)27 
Primary PCI 
 
 
30%  
(95% CI: 15,42) 
 
OR=0.70 (95% CI: 0.58,0.85); 
RRR=30% (95% CI: 15,42) 
outcome compares primary 
angioplasty to thrombolytics. 
 
Keeley (2003)28 
 
Beta blockers 4%  
(95% CI: -8,15) 
OR=0.96 (95% CI: 0.85,1.08); 
RRR=4% (95% CI: -8,15) on 
page 1732 
 
Freemantle (1999)29 
ACE inhibitors 7%  
(95% CI: 2,11) 
OR=0.93 (95% CI: 0.89,0.98); 
RRR=7% (95% CI: 2,11) for 30 
day mortality in myocardial 
infarction 
 
ACE Inhibitor 
Myocardial Infarction 
Collaborative Group 
(1998)30 
 
Clopidogrel 3%  
(95% CI: 1,6)  
RRR=3% (95% CI: 1,6) for 30 
day mortality in myocardial 
infarction 
 
Chen (2005)31 
Sabatine (2005)32 
Hospital CPR 
 
 
33%  
(95% CI: 10,36) 
Survival at 24 hours estimated 
to be 32%, discharge to home 
at 21%, and 1 year survival to 
be 15% overall. 
 
Tunstall-Pedoe 
(1992)33 
Nadkarni (2006)34 
Non-ST-segment elevation acute coronary syndrome (NSTEACS): 
 
    
Aspirin alone 15% 
(95% CI: 11,19) 
OR=0.85 (95% CI: 0.49,0.95); 
RRR=15% (95% CI: 11,19). 
Outcome is vascular and 
nonvascular deaths on page 75. 
Assume appropriate for patients 
with NSTE-ACS. 
 
Antithrombotic 
Trialists’ Collaboration 
(2002)35 
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Aspirin & 
heparin 
33% 
(95% CI: -2,56) 
OR=0.67 (95% CI: 0.48,1.02); 
RRR=33% (95% CI: -2,56%) in 
Table 2. The study outcome is 
composite MI death and non-
fatal MI; compares those on 
aspirin & heparin to aspirin 
only. 
 
Oler (1996)36 
Platelet 
glycoprotein 
IIB/IIA 
inhibitors 
9%  
(95% CI: 2,16) 
OR=0.91 (95% CI: 0.84,0.98); 
RRR=9% (95% CI: 2,16). 
Study looked at acute coronary 
syndrome without persistent ST 
elevation. 
 
Boersma (2002)37  
Early PCI 
 
32%  
(95% CI: 5,51) 
OR=0.68 (95% CI: 0.49,0.95); 
RRR=32% (95% CI: 5,51) 
 
Fox (2005)38  
Primary CABG 
surgery 
39%  
(95% CI: 23,52) 
OR=0.61 (95% CI: 0.48,0.77); 
RRR=39% (95% CI: 23,52) on 
page 565, 0-5 year mortality 
 
Yusuf (1994)27 
Assumed similar as 
STEMI 
 
Clopidogrel 
 
7% 
(95% CI: 2,11)  
RRR=7% (95% CI: 2,11) Yusuf (2001)39 
Beta blockers 4%  
(95% CI: -8,15) 
OR=0.96 (95% CI: 0.85,1.08); 
RRR=4% (95% CI: -8,15) on 
page 1732 
 
Freemantle (1999)29 
Assumed similar as 
STEMI 
 
ACE inhibitors 7%  
(95% CI: 2,11) 
OR=0.93 (95% CI: 0.89,0.98); 
RRR=7% (95% CI: 2,11) for 30 
day mortality in myocardial 
infarction 
 
ACE Inhibitor 
Myocardial Infarction 
Collaborative Group 
(1998)30 
 
Secondary prevention post myocardial infarction/revascularisation: 
 
    
Aspirin 15%  
(95% CI: 11,19) 
OR=0.85 (95% CI: 0.49,0.95); 
RRR=15% (95% CI: 11,19). 
Outcome is vascular and 
nonvascular deaths on page 75. 
This data seems to be 
appropriate to this outcome in 
CHD patients. 
 
Antithrombotic 
Trialists’ Collaboration 
(2002)35 
 
Beta blockers 23%  
(95% CI: 15,31) 
OR=0.77 (95% CI: 0.69,0.85); 
RRR=23% (95% CI: 15,31) on 
page 1734. Odds of death in 
long term trials. 
 
Freemantle (1999)29   
ACE inhibitors 
or Angiotensin-
II receptor 
antagonists 
20%  
(95% CI: 13,26) 
OR=0.80 (95% CI: 0.74,0.87); 
RRR=20% (95% CI: 13,26) on 
page 1577, death up to four 
years [endpoint of study looking 
at those with heart failure or LV 
dysfunction]. 
 
Flather (2000)40 
Statins 24%  
(95% CI: 10,26) 
RRR=24% (95% CI: 10,26) 
Intensive statin therapy in 
acute coronary syndromes. 
 
Hulten (2006)41 
 
Warfarin 22%  
(95% CI: 13,31) 
OR=0.78 (95% CI: 0.67,0.90); 
RRR=22% (95% CI: 10,33) 
 
Anand and Yusuf 
(1999)42  
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Rehabilitation 26%  
(95% CI: 10,39) 
OR=0.74 (95% CI: 0.61,0.90); 
RRR=26% (95% CI: 10,39) in 
Figure 1, page 685 Taylor 
reference 
 
Taylor (2004)43  
Chronic stable coronary artery disease: 
 
    
CABG surgery 
years 0-5 
 
39%  
(95% CI:23,52) 
OR = 0.61 (95% CI: 0.48-
0.77), RRR 39% (95% CI: 
23,52) on page 565, 5 year 
mortality 
 
Yusuf (1994)27  
CABG surgery 
years 6-10 
 
32%  
(95% CI: 2,30) 
OR = 0.83 (95% CI: 0.70-
0.98), RRR 17% (95% CI: 
2,30) on page 565, 10 year 
mortality. 
OR = 0.68 (95% CI: 0.56-
0.83), RRR 32% (95% CI: 
17,44) on page 565, 7 year 
mortality 
CABG compared to medical 
treatment 
 
Yusuf (1994)27  
Angioplasty  
 
No effect  Boden (2007)44 
Aspirin 
 
15%  
(95% CI: 11,19) 
OR=0.85 (95% CI: 0.49-0.95); 
RRR=15% (95% CI: 11,19). 
Outcome is vascular and 
nonvascular deaths on page 75. 
 
Antithrombotic 
Trialists’ Collaboration 
(2002)35 
 
Statins 
 
23%  
(95% CI: 10,26) 
 
RRR=23% (95% CI 10,26) 
Standard dose statin therapy in 
coronary artery disease. 
 
Wilt (2004)45 
 
ACE 
inhibitors/ARB 
 
 
 
 
17%  
(95% CI: 6,28) 
RRR=17% (95% CI 6,28) Al-Mallah (2006)46  
Heart failure in patients requiring hospitalisation or in the community: 
 
    
ACE inhibitors 20%  
(95% CI: 13,26) 
OR=0.80 (95% CI: 0.74,0.87); 
RRR=20% (95% CI: 13,26) on 
page 1577 [death up to four 
years was study endpoint for 
those with heart failure or LV 
dysfunction] 
 
Flather (2000)40 
Beta blockers 35%  
(95% CI: 26,43) 
OR=0.65 (95% CI: 0.57,0.74); 
RRR=35% (95% CI: 26,43): all 
cause mortality 
 
Shibata (2001)47 
Spironolactone 30%  
(95% CI: 18,41) 
 
31%  
(95% CI: 18,42) 
OR=0.70 (95% CI: 0.59,0.82); 
RRR=30% (95% CI: 18,41) in 
those that had at least one 
cardiac related hospitalisation.  
OR=0.69 (95% CI: 0.58,0.82); 
RRR=31% (95% CI: 18,42) in 
Pitt (1999)48 
34 
 
entire study population 
consisting of those with 
community heart failure, page 
711. 
 
Aspirin 15%  
(95% CI: 11,19) 
OR=0.85 (95% CI: 0.49,0.95); 
RRR=15% (95% CI: 11,19). 
Outcome is vascular and 
nonvascular deaths on page 75. 
 
Antithrombotic 
Trialists’ Collaboration 
(2002)35 
 
Statins 
 
 
No effect  Kjekshus (2007)49 
Tavazzi (2008)50 
Primary prevention therapies: 
 
    
Treatments for 
high blood 
pressure 
13% (95% CI: 
6,19) 
OR=0.87 (95% CI: 0.81,0.94); 
RRR=13% (95% CI: 6,19) in 
those with high blood pressure 
without disease at entry. 
[RRR=29% (95% CI: 17,37) 
those with average blood 
pressure and CHD, treated with 
ACE inhibitors] 
 
Law (2003)51 
Statins 35% (95% CI: 
11,52) 
OR=0.65 (95% CI: 0.48,0.89); 
RRR=35% (95% CI: 11,52) for 
CHD mortality (only trials using 
statins), Figure 3 on page 4 
 
Pignone (2000)52 
aRelative risk reduction (RRR) calculated as 1 – odds ratio	
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Table G. Case fatality rates for each patient group 
 
Age and gender specific one year case-fatality rates were required for each patient 
group. Where possible these were estimated using the linked Scottish Morbidity Record 
(SMR01) and death record dataset provided by Information Services Division Scotland. 
It was possible to estimate Scottish specific case fatality rates for the following disease 
groups: DG1: STEMI; DG2: nSTEACS; DG6: Hospital HF with CHD; DG3: Post MI in 
community and DG4: Post revascularization in the community (no MI) split into CABG 
and PCI. Previously published data was utilised for the following disease groups DG5: 
chronic stable coronary artery disease; DG7: heart failure in the community; DG8: 
Statin medication for primary prevention and DG9: Anti-hypertensive medication for 
primary prevention.6 
 
Historical/baseline one year case fatality rates were estimated for disease groups 1 
(AMI), 2 (UA) and 6 (HF with CHD) using linked SMR01 data from 1986; before major 
changes in therapy/diagnosis. The linked data enabled individuals to be followed for 0 
to 365 days after the index event. The use of data from 1986 enabled look back to 
1981 in order to exclude pre-existing conditions. Index admissions (main diagnosis and 
first admission of year) during 1986 were assigned to the three mutually exclusive 
disease groups adhering to the hierarchy HF>AMI>UA. It was then identified what 
proportion of these patients died within 365 days (all-cause death). The following 
disease definitions were used to identify index admissions: 
DG1: STEMI using emergency AMI (ICD9 410; ICD10 I21) as proxy for STEMI 
DG2: nSTEACS using emergency UA (ICD9 4111 or 413_; ICD10 I21) as proxy for 
nSTEACS 
DG6: Hospital HF with previous CHD since 1981 using HF (ICD9 4280 or 4281 or 
4289 ICD10 I50) with a previous admission for CHD (ICD9 410 or 411 or 412 or 414; 
ICD10 I21 or I22 or I23 or I24) as well as previous CABG (OCPS3 3043). 
 
One year case fatality rates were created for the DG3 and DG4 community groups 
using data from 1981 to 1995 from the linked SMR01 and death record dataset. This 
was selected as it allowed a longer period of look back plus angioplasty was not coded 
until 1989. Patients were assigned to disease groups using the following hierarchy: 
Post AMI> Post CABG >Post PCI. All patients with index events up to 31st December 
1994 and alive on 1st January 1995 were identified and the proportion that died within 
365 days determined. The following disease definitions were used to identify index 
admission: 
DG3: Post MI in community using AMI (ICD9 410) 
DG4: Post revascularisation in community (no MI) divided into CABG (pre 1989 
OCPS3 3043 or post 1989 OPCS4 K40 or K41 or K42 or K43 or K44 or K45 or K46) and 
PCI (post 1989 K49 or K501 or K75). 
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Table G. Case fatality rates for each patient group 
 
 Source: Information Services Division (ISD) – linked SMR01 and 
death record dataset 
Source: Wijeysundera et.al (2010) 6 
 
Patient 
group 
 
AMI 
 
POST 
AMI 
 
ACS 
(UA) 
 
 
Post 
revascularisation 
 
Heart 
failure in 
hospital 
associat
ed with 
CHD 
 
Chronic 
stable 
coronary 
artery 
disease 
 
Heart 
failure in 
community 
 
Hyper- 
tension 
 
Hyper-
choleste
rolaemia 
CABG PTCA  
Interval 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 1 year 
           
Men           
  25-34 0.120 0.008 0.000 0.000 0.000 0.000 0.006 0.04 0.000 0.000 
  35-44 0.082 0.010 0.028 0.005 0.013 0.389 0.009 0.04 0.001 0.001 
  45-54 0.126 0.017 0.039 0.008 0.003 0.393 0.012 0.06 0.002 0.002 
  55-64 0.230 0.027 0.054 0.015 0.015 0.446 0.016 0.08 0.006 0.006 
  65-74 0.383 0.047 0.102 0.035 0.029 0.520 0.029 0.13 0.014 0.014 
  75-84 0.543 0.097 0.119 0.047 0.034 0.553 0.065 0.20 0.035 0.035 
   85+ 0.782 0.152 0.091 0.000 0.000 0.620 0.163 0.32 0.094 0.094 
           
Women           
  25-34 0.250 0.022 0.000 0.000 0.000 0.000 0.007 0.05 0.000 0.000 
  35-44 0.121 0.007 0.000 0.000 0.000 0.143 0.007 0.05 0.001 0.001 
  45-54 0.129 0.015 0.013 0.000 0.011 0.313 0.010 0.05 0.002 0.002 
  55-64 0.226 0.022 0.039 0.015 0.005 0.393 0.014 0.08 0.004 0.004 
  65-74 0.375 0.042 0.068 0.019 0.022 0.476 0.025 0.12 0.014 0.014 
  75-84 0.530 0.076 0.146 0.037 0.071 0.582 0.054 0.17 0.035 0.035 
  85+ 0.628 0.143 0.207 0.000 0.000 0.570 0.155 0.30 0.094 0.094 
           
AMI – Acute Myocardial infarction; ACS – Acute coronary syndrome; UA – unstable angina; CHD – coronary heart disease; 
CABG – coronary artery bypass graft; PTCA – Percutaneous transluminal coronary angioplasty 
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Table H. Treatment uptake in 2000 and 2010a 
 
 National  SIMD  Q1 SIMD Q2 SIMD Q3 SIMD Q4 SIMD Q5 
 N Uptake (%) N Uptake (%) N Uptake (%) N Uptake (%) N Uptake (%) N Uptake (%) 
  2000 2010  2000 2010  2000 2010  2000 2010  2000 2010  2000 2010 
ST elevation myocardial infarction (STEMI): 
Thrombolysis 2502 77.6 58.5 360 79.7 60.5 479 78.0 62.1 511 75.9 59.4 552 76.3 57.4 600 78.7 54.5 
Aspirin 2502 93.6 96.6 360 93.7 97.0 479 94.6 96.9 511 93.0 96.1 552 93.1 96.4 600 93.8 96.8 
B-Blocker 2502 71.7 72.8 360 75.2 72.9 479 72.6 71.9 511 71.4 72.0 552 69.7 72.1 600 71.4 74.7 
ACE I/ARB 2502 77.5 78.3 360 79.8 78.4 479 79.0 77.4 511 75.9 77.5 552 75.5 77.0 600 78.5 80.9 
Clopidogrel 2502 28.1 90.0 360 27.1 90.2 479 25.8 89.3 511 28.0 90.3 552 29.1 89.9 600 29.2 90.4 
Primary PCI 2502 4.2 58.6 360 6.2 66.7 479 4.0 58.4 511 4.1 55.8 552 5.0 56.2 600 2.6 58.4 
Primary CABG 2502 0.0 0.1 360 0.0 0.3 479 0.2 0.0 511 0.0 0.0 552 0.0 0.2 600 0.0 0.0 
Hospital CPR 2502 11.2 5.8 360 9.8 5.8 479 11.4 6.1 511 11.7 5.5 552 11.7 5.9 600 11.1 5.6 
Community CPR 1316 23.4 28.3 185 9.8 5.8 239 11.4 6.1 260 11.7 5.5 288 11.7 5.9 344 11.1 5.6 
Non-ST-segment elevation acute coronary syndrome (NSTEACS): 
Aspirin & heparin 9108 64.0  79.9  1251 67.4  79.7  1650 65.6  80.7  1867 67.0  80.1  2091 65.9  80.1  2249 58.0  78.9  
Aspirin alone 9108 24.3  12.8  1251 21.4  13.6  1650 23.5  12.2  1867 21.4  12.6  2091 23.4  12.5  2249 28.8  13.1  
Platelet glycoprotein 
IIB/IIIA inhibitors 
9108 6.0 5.9 1251 9.6 6.3 1650 7.4 6.0 1867 6.3 5.3 2091 4.8 5.1 2249 4.6 7.0 
ACE I/ARB 9108 66.2  73.5  1251 68.8  73.3  1650 64.3  72.6  1867 66.2  72.8  2091 64.5  72.8  2249 67.7  75.2  
B-Blocker 9108 63.9  67.9  1251 66.9  68.3  1650 63.5  68.3  1867 64.2  67.1  2091 62.5  66.2  2249 63.9  69.5  
Clopidogrel 9108 45.1  86.8  1251 44.0  87.3  1650 44.7  87.4  1867 43.0  87.1  2091 46.2  86.0  2249 46.4  86.5  
CABG (< 6 weeks) 9108 0.4  0.4  1251 0.9  0.3  1650 0.4  0.6  1867 0.3  0.5  2091 0.4  0.3  2249 0.4  0.2  
PCI (0-14 days) 9108 3.5  6.7  1251 5.6  7.9  1650 3.1  7.8  1867 4.2  6.2  2091 3.3  5.9  2249 2.6  6.4  
Hospital CPR 4638 5.2  2.4  712 4.5  2.3  908 4.8  2.2  955 5.3  2.2  1029 5.5  2.7  1034 5.5  2.4  
Secondary prevention post myocardial infarction: 
Aspirin 60197 68.6  80.5  9282 67.4  80.0  10490 69.1  78.8  12023 67.3  78.8  13872 69.3  80.9  14530 69.2  83.3  
B-Blocker 60197 45.7  65.8  9282 50.9  67.5  10490 45.5  63.3  12023 47.5  64.2  13872 44.0  65.3  14530 43.1  68.6  
ACE I/ARB 60197 26.5  68.0  9282 26.4  68.3  10490 29.2  67.1  12023 26.6  64.5  13872 26.7  69.2  14530 24.6  70.2  
Statin 60197 41.7  86.6  9282 43.4  84.9  10490 44.2  84.6  12023 40.9  85.7  13872 41.6  87.0  14530 39.8  89.5  
Warfarin 60197 4.7  6.0  9282 5.3  6.5  10490 5.9  6.0  12023 4.9  6.9  13872 4.2  5.3  14530 4.0  5.7  
Rehabilitation 60197 17.1  42.1  9282 17.0  41.7  10490 17.0  41.9  12023 17.0  42.1  13872 17.1  42.0  14530 17.3  42.8  
Secondary prevention post revascularisation: 
Aspirin 40295 75.6  79.2  7538 72.5  75.1  7539 81.4  80.6  8128 70.3  78.5  8691 77.1  78.0  8399 76.8  83.8  
B-Blocker 40295 45.3  62.0  7538 48.5  60.3  7539 48.4  61.8  8128 47.1  62.4  8691 39.1  59.7  8399 44.9  65.9  
ACE I/ARB 40295 20.7  59.5  7538 21.8  56.9  7539 22.0  53.9  8128 16.3  60.3  8691 24.1  65.3  8399 19.4  60.2  
Statin 40295 62.4  90.9  7538 67.3  89.5  7539 62.6  88.5  8128 57.4  90.3  8691 63.8  92.3  8399 61.2  93.4  
Warfarin 40295 8.5  7.3  7538 6.0  8.3  7539 6.8  7.6  8128 11.2  8.1  8691 9.8  7.7  8399 8.1  5.0  
Rehabilitation (PTCA) 11099 7.5 12.4 2029 7.5 12.6 2141 7.5 12.4 2297 7.5 12.3 2344 7.5 12.4 2288 7.5 12.2 
Rehabilitation (CABG) 7113 42.5  41.9  1391 43.1  41.9  1414 42.6  42.4  1460 42.6  41.7  1519 42.5  42.0  1329 42.0  41.3  
Chronic stable coronary artery disease: 
Aspirin 72394 59.6  73.6  11705 57.7  71.4  13457 60.3  72.0  16889 57.4  72.2  15283 61.2  75.0  15061 60.7  77.2  
Statins 72394 28.7  78.6  11705 31.1  77.6  13457 27.6  76.3  16889 30.2  78.4  15283 28.9  81.7  15061 26.8  78.4  
ACE I/ARB 72394 15.3  45.2  11705 16.8  45.2  13457 15.7  45.1  16889 14.6  41.7  15283 15.7  47.9  15061 14.8  46.4  
CABG surgery (last 5 
years) 
72394 11.8 9.8 11705 16.0 11.9 13457 11.9 10.5 16889 10.2 8.6 15283 11.4 9.9 15061 11.4 8.8 
Heart failure in patients requiring hospitalisation: 
ACE I/ARB 3644 51.4  64.3  502 50.1  62.6  619 50.1  62.7  764 51.5  64.4  844 51.8  64.7  915 52.7  65.8  
B-Blocker 3644 31.9  45.6  502 31.0  44.2  619 31.1  44.4  764 32.0  45.7  844 32.2  46.0  915 32.7  46.7  
Spironolactone 3644 21.0  26.2  502 20.5  25.6  619 20.3  25.4  764 21.1  26.4  844 21.2  26.6  915 21.2  26.5  
Aspirin 3644 71.9  79.9  502 70.8  80.7  619 74.9  77.1  764 68.6  78.8  844 72.7  80.1  915 72.4  82.3  
Heart failure in the community: 
ACE I/ARB 16224 69.7  81.4  2243 72.6  79.7  2826 72.5  79.4  3271 61.5  79.3  3523 70.0  79.7  4362 72.7  86.5  
B-Blocker 16224 30.9  65.8  2243 34.3  57.3  2826 28.2  60.0  3271 32.8  66.9  3523 28.2  65.5  4362 32.1  73.3  
Spironolactone 16224 7.7  11.7  2243 6.2  7.8  2826 10.4  14.5  3271 6.6  12.7  3523 6.5  16.4  4362 8.2  7.4  
Aspirin 16224 74.3  75.1  2243 71.9  75.4  2826 71.8  76.9  3271 71.2  71.6  3523 77.8  73.7  4362 77.0  77.7  
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Primary prevention therapies: 
Anti-hypertension  3685544 12.2  18.3  735789 9.4  15.6  761624 12.4  19.3  755559 12.2  17.8  736790 12.9  18.8  695782 14.0  19.9  
Statins 3685544 2.7 15.1 735789 2.2 13.2 761624 2.8 15.8 755559 2.8 15.3 736790 2.6 14.3 695782 3.2 17.0 
                   
a For sources see Table A 
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Table I.  Beta coefficients for major risk factors 
 
Estimated β coefficients from multiple regression analyses for the relationship 
between absolute changes in population mean risk factors and percentage changes 
in coronary heart disease mortality for men and women, stratified by age. Data 
sources, values and comments. 
 
Systolic blood 
pressure 
Age group (years) 
 25-44 45-54 55-64 65-74 75+ 
      
Men (hazard ratio per 
20 mmHg) 
 
0.49 0.49 0.52 0.58 0.65 
Men (log hazard ratio 
per 1 mmHg) 
-0.036 -0.035 -0.032 -0.027 -0.021 
      
Minimum -0.029 -0.028 -0.026 -0.022 -0.017 
Maximum -0.043 -0.042 -0.039 -0.032 -0.025 
      
      
Women (hazard ratio 
per 20 mmHg) 
 
0.40 0.40 0.49 0.52 0.59 
Women (log hazard 
ratio per 1 mmHg) 
 
-0.046 -0.046 -0.035 -0.032 -0.026 
Minimum -0.037 -0.037 -0.028 -0.026 -0.021 
Maximum -0.055 -0.055 -0.042 -0.039 -0.031 
      
      
Source: Prospective studies collaborative meta-analysis, 
Lancet 200253 
Units: Percentage change in CHD mortality per 20 mmHg 
change in systolic blood pressure 
Strengths: Large dataset, includes US data, adjusted for 
regression dilution bias, consistent with randomized 
controlled trials, results stratified by age and sex, 
with 95% confidence intervals 
 
Limitations: Some publication bias still possible 
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Cholesterol Age groups (years) 
 
 25-44 45-54 55-64 65-74 75-84 85+ 
Mortality reduction per 1 mmol/l 
Men 0.55 0.53 0.36 0.21 0.21 0.21 
Women 0.57 0.52 0.35 0.23 0.23 0.23 
Log coefficient 
Men -0.799 -0.755 -0.446 -0.236 -0.117 -0.083 
Minimum -0.639 -0.604 -0.357 -0.189 -0.093 -0.067 
Maximum -0.958 -0.906 -0.536 -0.283 -0.140 -0.100 
       
Women -0.844 -0.734 -0.431 -0.261 -0.174 -0.051 
Minimum -0.675 -0.587 -0.345 -0.209 -0.139 -0.041 
Maximum -1.013 -0.881 -0.517 -0.314 -0.209 -0.062 
Source: Prospective studies collaborative meta-analysis, 
Lancet 200754 
Units: Percentage change in CHD mortality per 1 mmol/l 
change in total cholesterol 
Strengths: Includes US data, adjusted for regression dilution 
bias, includes randomized controlled trials, RCT 
values consistent with observational data, results 
stratified by age and sex, with 95% confidence 
intervals 
Limitations: Some publication bias still possible 
 
Body Mass Index (BMI) 
 
Age groups (years) 
 <44 45-59 60-69 70-79 80+ 
James et.al (2004):      
Hazard ratio 0.89 0.91 0.95 0.96 0.97 
Risk reductiona per 1 kg/m2 0.11 0.09 0.05 0.04 0.03 
Age gradient (45-59 as 
reference) 
1.22 1.00 0.56 0.44 0.33 
Bogers (2006):  
Relative risks, CHD deaths 
per 5 BMI units (kg/m2) 
  
1.16 
   
Relative risks per 1 kg/m2 
applying age gradients from 
James et.al  
1.04 1.03 1.02 1.01 1.01 
Log coefficients 0.0363 0.0297 0.0165 0.0132 0.0099 
Minimum 0.0255 0.0209 0.0116 0.0093 0.0070 
Maximum 0.0466 0.0381 0.0212 0.0169 0.0127 
Source: Bogers et al (2006)55, James et al (2004)56    
Units: Percentage change in CHD mortality per 1 kg/m2 
change in BMI 
Strengths: Large number of studies included. Adjusted for 
blood pressure, total cholesterol, and physical 
activity. 95% confidence intervals included. 
Limitations: Observational data; age gradient applied from 
James study 
a Risk reduction = 1 – hazard ratio 
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Table J. Relative risk for CHD mortality: smoking, diabetes and 
physical inactivity 
 
Calculation of Relative Risk estimates for dichotomous risk factors in the 
IMPACTSEC model 
Relative risks (RRs) estimated by expert working groups for the World Health 
Organization’s (WHO) Global Burden of Disease (GBD) 2001 Study were used for 
smoking and physical activity10 Effect estimates were based on systematic reviews of 
cohort studies (adjusted for regression dilution bias) and meta-analyses of 
randomised controlled trials. Age-variation in the relative risks for diabetes were 
taken from the DECODE study.11 These were then applied to the sex-variation in 
relative risks estimated by Huxley et al.12 The set of RRs used in the IMPACTSEC 
model for the three binary risk factors with 95% Confidence Intervals (in 
parentheses) are shown below. RRs were assumed constant across deprivation 
quintiles.  
 
 Smoking Physical 
inactivity 
Diabetes 
Male 25-34 5.51 (2.47-12.25) 1.50 (1.35-1.67) 4.33 (3.47-5.20) 
Male 35-44 5.51 (2.47-12.25) 1.50 (1.35-1.67) 3.22 (2.58-3.86) 
Male 45-54 3.04 (2.66-3.48) 1.50 (1.35-1.67) 2.14 (1.71-2.57) 
Male 55-64 2.51 (2.22-2.84) 1.50 (1.35-1.67) 1.99 (1.59-2.39) 
Male 65-74 1.69 (1.52-1.89) 1.44 (1.30-1.61) 1.86 (1.49-2.23) 
Male 75-84 1.31 (1.11-1.56) 1.32 (1.19-1.47) 1.71 (1.37-2.05) 
Male 85+ 1.05 (0.78-1.43) 1.23 (1.11-1.37) 1.71 (1.37-2.05) 
Female 25-34 2.26 (0.83-6.14) 1.50 (1.35-1.68) 7.55 (6.04-9.06) 
Female 35-44 2.26 (0.83-6.14) 1.50 (1.35-1.68) 5.63 (4.51-6.76) 
Female 45-54 3.78 (3.10-4.62) 1.50 (1.35-1.68) 3.81 (3.05-4.57) 
Female 55-64 3.21 (2.70-3.82) 1.50 (1.35-1.68) 3.12 (2.50-3.74) 
Female 65-74 2.17 (1.89-2.47) 1.45 (1.30-1.61) 2.55 (2.04-3.06) 
Female 75-84 1.58 (1.33-1.88) 1.33 (1.20-1.47) 2.36 (1.89-2.83) 
Female 85+ 1.38 (1.08-1.77) 1.24 (1.13-1.37) 2.36 (1.89-2.83) 
 
In Section J.1 we list the published RRs for each of the three risk factors; in Section 
J.2 we detail how these were modified to fit to the age-sex distributions used in the 
IMPACTSEC model. 
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J.1 Published relative risks 
 
1 Current smoking 
 
Relative risk of mortality from Ischaemic Heart Disease (ICD9: 410-414) for current 
smokers relative to non-smokers (95% CIs in parentheses), from the American 
Cancer Society’s Cancer Prevention Study (CPS-II) 
 
Age Male Female 
30-44 5.51 (2.47-12.25) 2.26 (0.83-6.14) 
45-59 3.04 (2.66-3.48) 3.78 (3.10-4.62) 
60-69 1.88 (1.70-2.08) 2.53 (2.22-2.87) 
70-79 1.44 (1.27-1.63) 1.68 (1.46-1.93) 
≥ 80 years 1.05 (0.78-1.43) 1.38 (1.08-1.77) 
 
Notes: CPS-II is an ongoing prospective study of mortality in 1.2 million Americans 
aged 30 years or more when they completed a questionnaire on tobacco and alcohol 
use, diet, and multiple other factors affecting health and mortality in 1982. RRs were 
estimated from Cox proportional-hazard models, with non-smokers as the reference 
group (RR=1.0 for non-smokers). Risks were adjusted for age, race, education, 
marital status, “blue collar” employment in most recent or current job, weekly 
consumption of vegetables and citrus fruit, vitamin (A, C, and E) use, alcohol use, 
aspirin use, body mass index, exercise, dietary fat consumption and for hypertension 
and diabetes (both at baseline). Analyses of the hazards associated with smoking 
were based on the first six years of follow-up (1982 through 1988). 
 
Source: Ezzati et al (2005)57  
 
2 Physical inactivity 
 
Relative risk of Ischaemic Heart Disease (ICD10: I20-I25) from physical (in)activity 
levels from WHO GBD Study (95% CIs in parentheses), relative to those considered 
physically active 
 
Age Inactive level Insufficiently active level 
15-69 1.71 (1.58-1.85) 1.44 (1.28-1.62) 
70-79 1.50 (1.38-1.61) 1.31 (1.17-1.48) 
80+ years 1.30 (1.21-1.41) 1.20 (1.07-1.35) 
 
Notes: Physical (in)activity in the WHO GBD study was treated as a categorical 
variable with three categories: Level 1: Inactive: ‘doing no or very little physical 
activity at work, at home, for transport, or during discretionary time’. Level 2: 
Insufficiently active: ‘doing some physical activity but less than 150 minutes of 
moderate-intensity physical activity or 60 minutes of vigorous-intensity physical 
activity a week accumulated across work, home, transport or discretionary domains’. 
Level 3: Sufficiently active (unexposed): ‘at least 150 minutes of moderate-intensity 
physical activity or 60 minutes of vigorous-intensity physical activity a week 
accumulated across work, home, transport or discretionary domains’, which 
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approximately corresponds to current recommendations in many countries. RR 
estimates were adjusted for confounding variables, measurement error associated 
with self-report, and attenuated over age (25% of the excess risk for the 70-79 year 
age-group and 50% of the excess risk for the oldest age group, 80+), but not 
adjusted for blood pressure and cholesterol. 
 
Sources: Bull et al (2004)58; Joubert et al (2007)59 
 
3 Diabetes 
 
A meta-analysis of 22 prospective cohort studies by Huxley et al12 estimated that the 
relative risk for CHD due to diabetes was 1.99 (95% CI: 1.69-2.35) in men and 3.12 
(2.34-4.17) in women. These estimates were derived from studies that provided 
multiple risk factor adjusted coefficients. This systematic review included Asia-Pacific 
studies with larger RR values compared to Western studies, although the difference 
was not statistically significant. To obtain age-specific relative risk estimates, we 
used the age-gradients in relative risk for total mortality for diabetic persons 
compared to non-diabetics taken from the DECODE study as detailed below. 
 
Estimates of relative risk for total mortality due to diabetes (DECODE study) 
 
Age Males Females 
20-29 3.66 6.05 
30-39 3.38 5.41 
40-49 1.85 3.14 
50-59 1.63 2.64 
60-69 1.60 2.04 
70-79 1.39 1.79 
 
Notes: Undertaken in 1997, the Diabetes Epidemiology: Collaborative Analysis of 
Diagnostic Criteria in Europe (DECODE) study built a dataset that included the 
baseline values needed to determine the presence of the metabolic syndrome using a 
modification of the WHO definition for 11 European study cohorts, and follow-up data 
on all-cause and cardiovascular disease mortality60.  
 
Source: Roglic and Unwin (2010)11 
	
J.2 Adjusting the published RR values 
The published relative risk values outlined in the previous section were adjusted to 
conform to the age distributions and binary classification of risk used in the 
IMPACTSEC study. Table J above shows the final, adjusted RR values used in our 
model to estimate the Population Attributable Risk Fractions. Below we detail how 
the adjustments to the published RR values were calculated. 
 
Weighted averages using the European Standard Population 
We adjusted the RRs for each binary risk factor to match the ten-year age-bands 
used in our study. A population-weighted approach, using weights from the European 
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Union (EU) reference population, was used to estimate the RRs for each of the 7 age-
bands. We used the EU standard reference population for two reasons: first, for 
consistency. The EU standard was used as the reference population distribution in all 
IMPACTSEC and related studies to calculate directly-standardised rates. Secondly, 
using the EU reference population aids comparability. The ensuing age-weighted 
rates can easily be used in studies in other European countries with a similar 
population structure and results compared against each other or with other health 
statistics (e.g. mortality rates) standardised using the same reference population. 
  
1 Adjustment to published RRs for current smoking 
The population-weighted adjustment approach is illustrated below using the RRs for 
current smoking in men as an example. For example, the RR value used in our model 
for males aged 55-64 was 2.51. This is roughly, but not exactly, halfway between 
the CPS-II estimates of 3.04 and 1.88 for males aged 55-59 and 60-64 with 
population weights of 0.545 and 0.455, respectively. The same calculations using a 
population weighted approach were performed using the CPS-II 95% confidence 
intervals to estimate the standard error of the RRs to use as input to the Ersatz 
Relative Risk function (See Table M). 
 
Age 
bands for 
IMPACTSEC 
5 year 
age-
bands 
EU 
population 
EU population 
weight 
CPS-II RR IMPACTSEC 
RR 
M 25-34 M 25-29 7000 0.5 5.51 5.51 
M 30-34 7000 0.5 5.51 
M 35-44 M 35-39 7000 0.5 5.51 5.51 
M 40-44 7000 0.5 5.51 
M 45-54 M 45-49 7000 0.5 3.04 3.04 
M 50-54 7000 0.5 3.04 
M 55-64 M 55-59 6000 0.545 3.04 2.51 
M 60-64 5000 0.455 1.88 
M 65-74 M 65-69 4000 0.571 1.88 1.69 
M 70-74 3000 0.429 1.44 
M 75-84 M 75-79 2000 0.667 1.44 1.31 
M 80-84 1000 0.333 1.05 
M 85+ 1000 1 1.05 1.05 
 
2 Adjustment to published RRs for physical activity 
We adjusted the published RRs for physical activity to employ a dichotomous rather 
than trichotomous measure (i.e. combining the GBD ‘insufficiently active’ and 
‘inactive’ categories into a single inactive group). We used a weighted average 
approach using as weights the GBD estimates of exposure to physical inactivity in 
the EUR-A subregion (Table 10.10 in Bull et al, 2004)58. The physical activity 
exposure levels (%) with the corresponding RR value (RR=1 for the Level 3 
‘sufficiently active’ group) shown in parentheses are detailed below. 
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Physical activity exposure levels (%) in the GBD EUR-A regiona with 
accompanying RRs 
 
Exposure 
category 
Age-group (years) 
15-29 30-44 45-59 60-69 70-79 ≥ 80 
years 
Men:       
Level 3: 
Recommended 
35 (1) 29 (1) 30 (1) 30 (1) 30 (1) 32 (1) 
Level 2: 
Insufficient 
52 (1.44) 57 (1.44) 55 (1.44) 52 (1.44) 50 (1.31) 47 (1.20) 
Level 1: 
Inactive 
13 (1.71) 15 (1.71) 16 (1.71) 18 (1.71) 20 (1.50) 21 (1.30) 
Levels 1 and 2  
(combined RR) 
1.49 1.50 1.50 1.51 1.36 1.23 
       
Women:       
Level 3: 
Recommended 
37 (1) 31 (1) 31 (1) 33 (1)  31 (1) 30 (1) 
Level 2: 
Insufficient 
47 (1.44) 51 (1.44) 51 (1.44) 45 (1.44) 45 (1.31) 42 (1.20) 
Level 1: 
Inactive 
17 (1.71) 18 (1.71) 18 (1.71) 22 (1.71) 24 (1.50) 28 (1.30) 
Levels 1 and 2  
(combined RR) 
1.51 1.51 1.51 1.53 1.38 1.24 
 
Notes: For example, using the GBD estimates of exposure and RRs, the combined RR 
for males aged 45-59 equalled 1.50: 
 
RR (combining insufficient and inactive):  
        ((0.55×1.44)+(0.16×1.71))/(0.55+0.16) = 1.50 
 
a Countries in the EUR-A GBD subregion: Andorra, Austria, Belgium, Croatia, Czech 
Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, 
Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, 
Spain, Sweden, Switzerland, United Kingdom 
  
Source: Bull et al (2004)58 
 
Due to negligible differences in the combined RRs across the youngest age categories 
we used a relative risk of 1.50 for men and women aged 25-69. Having used the 
GBD data to obtain a set of RRs for a binary physical activity variable in each of 
three broad age-groups (25-69, 70-79, 80+) we then used the population-weighted 
average approach, using weights from the EU population, to estimate the combined 
RRs for the seven ten-year age-bands used in IMPACTSEC. This is illustrated below for 
males. The same sets of calculations using a population weighted approach were 
performed using the GBD 95% confidence intervals to estimate the standard error of 
the RRs to use as input into the Ersatz Relative Risk function (See Table M). 
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Age bands 
for 
IMPACTSEC 
5 year 
age-
bands 
EU 
populatio
n 
EU 
population 
weight 
Combined 
inactive 
RR 
 
IMPACTSEC 
RR 
M 25-34 M 25-29 7000 0.5 1.50 1.50 
M 30-34 7000 0.5 1.50 
M 35-44 M 35-39 7000 0.5 1.50 1.50 
M 40-44 7000 0.5 1.50 
M 45-54 M 45-49 7000 0.5 1.50 1.50 
M 50-54 7000 0.5 1.50 
M 55-64 M 55-59 6000 0.545 1.50 1.50 
M 60-64 5000 0.455 1.50 
M 65-74 M 65-69 4000 0.571 1.50 1.44 
M 70-74 3000 0.429 1.36 
M 75-84 M 75-79 2000 0.667 1.36 1.32 
M 80-84 1000 0.333 1.23 
M 85+ 1000 1 1.23 1.23 
 
3 Adjustment to published RRs for diabetes 
Unlike the relative risk estimates for smoking and physical activity, the meta-analysis 
of 22 prospective cohort studies by Huxley et al12 provided just overall estimates of 
RR for diabetes by gender. From previous studies we know that the relative risks 
associated with diabetes are higher for women and decline with age. To obtain age 
variation in the diabetes RRs, we used the age-gradient in the RR estimates for total 
mortality taken from the DECODE study.11 As diabetes is a proximate risk factor for 
cardiovascular disease, and cardiovascular disease comprises about half of total 
mortality61, we have assumed that the relative age pattern of diabetes-related CHD 
mortality will be similar. We made the reasonable assumption that the mean age 
across the prospective studies examined in the meta-analysis by Huxley et al12  was 
age 55-64 years. Hence the age-adjusted values were anchored to this age group for 
both sexes.  
 
To estimate the relative risks for diabetes, we first used the DECODE study estimates 
to compute the age gradient in RRs, indexed on the value for the 55-64 age-group. 
The resulting value for each age group was then multiplied by the overall RR for men 
and women (1.99 and 3.12, respectively) taken from the study by Huxley et al12 to 
give the age-specific RR of CHD mortality for diabetes. For ages 80 and over (for 
which published RRs were not found), we have assumed that the RR remained the 
same as for those aged 70-79. Detailed below is the worked example for males. 
Estimates of the 95% confidence intervals were not provided for the RRs taken from 
the DECODE study.11 Hence, similar to previous IMPACT models, we used ± 20% of 
the point estimate as an approximation of the 95% confidence interval. We then 
used this interval to derive the standard error of the RR to use as an input parameter 
in the Ersatz uncertainty analysis. This value was equal to 0.103 - a value lying 
reasonably close to the average of the standard errors around the sex-specific 
estimates from Huxley et al.12 
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Age-
bands for 
IMPACTSEC 
5 year 
age 
bands 
EU pop EU pop 
weight 
RR from 
DECODE 
study 
Weighted 
RRs from 
DECODE 
Age 
variation 
from 
DECODEa 
IMPACTSEC 
RRsb 
M 25-34 M 25-29 7000 0.5 3.66 3.5 2.18 4.33 
M 30-34 7000 0.5 3.38 
M 35-44 M 35-39 7000 0.5 3.38 2.6 1.62 3.22 
M 40-44 7000 0.5 1.85 
M 45-54 M 45-49 7000 0.5 1.85 1.7 1.08 2.14 
M 50-54 7000 0.5 1.63 
M 55-64 M 55-59 6000 0.545 1.63 1.6 1.00 1.99 
M 60-64 5000 0.455 1.60 
M 65-74 M 65-69 4000 0.571 1.60 1.5 0.93 1.86 
M 70-74 3000 0.429 1.39 
M 75-84 M 75-79 2000 0.667 1.39 1.4 0.86 1.71 
M 80-84 1000 0.333 1.39 
M 85+  1000 1 1.39 1.4 0.86 1.71 
Notes:  
a 55-64 age-group taken as the reference 
b IMPACTSEC RR calculated as sex-specific RR from Huxley et al (2006)12 (men:1.99; 
women:3.12) multiplied by age-variation in EU weighted RRs taken from DECODE 
study11 
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Table K. Observed risk factor levels in 2000 and 2010 by sex and deprivation quintiles 
 
 Scotland SIMDQ1 SIMDQ2 SIMDQ3 SIMDQ4 SIMDQ5 
 2000 2010 2000 2010 2000 2010 2000 2010 2000 2010 2000 2010 
Smoking prevalence, %            
Male 30.3 26.0 19.9 17.1 25.1 21.6 30.2 25.9 34.3 29.4 39.0 33.5 
Female 28.9 23.7 17.7 14.5 22.3 18.3 28.6 23.5 32.8 27.0 39.0 32.0 
Diabetes prevalence, %            
Male 4.2 7.3 3.1 5.3 4.1 7.0 4.5 7.8 4.6 7.9 4.9 8.4 
Female 3.4 5.3 2.3 3.5 2.4 3.6 3.8 5.8 3.9 6.0 4.7 7.3 
Physical inactivity, %            
Male 66.3 58.9 66.7 59.2 65.4 58.1 64.9 57.8 66.0 58.6 68.1 60.3 
Female 74.6 68.4 71.9 65.9 73.7 67.5 74.1 68.0 75.8 69.6 77.0 70.5 
Systolic blood pressure, mmHg           
Male 133.1 132.2 132.6 131.6 133.7 132.8 133.4 132.4 132.6 131.7 133.5 132.7 
Female 130.1 126.9 128.8 125.7 129.6 126.5 130.4 127.3 130.9 127.6 131.1 128.0 
Cholesterol, mmol/L            
Male 5.6 5.2 5.7 5.3 5.6 5.2 5.6 5.2 5.5 5.1 5.5 5.1 
Female 5.7 5.4 5.8 5.5 5.7 5.4 5.8 5.5 5.7 5.4 5.6 5.4 
Body mass index, kg/m2            
Male 27.3 28.2 27.1 28.0 27.3 28.3 27.3 28.2 27.3 28.3 27.2 28.1 
Female 27.1 27.9 26.1 26.9 26.9 27.8 27.1 27.9 27.6 28.4 27.8 28.6 
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Tables L. Gender specific coronary heart disease deaths 
prevented or postponed between 2000 and 2010 
 
Table L.1 Coronary heart disease deaths prevented or postponed (DPPs) 
amongst men between 2000 and 2010 as percentage of men specific total 
DPPs to be explained, stratified by deprivation quintile 
 
Men 
Treatments by Patient Groups; 
Risk Factors Scotland 
Most 
Affluent SIMDQ2 SIMDQ3 SIMDQ4 
Most 
Deprived P-Value 
Treatments  
STEMI* 2.2 2.5 2.4 1.7 2.5 2.2 0.89 
NSTEACS* 1.3 1.0 1.5 1.0 1.4 1.5 0.53 
Secondary prevention post MI* 11.2 12.1 10.5 9.7 12.2 11.9 0.67 
Secondary prevention post revasc* 2.9 3.0 2.4 3.2 3.2 2.8 0.90 
Chronic stable CAD 5.1 5.6 5.9 4.4 6.0 4.0 0.27 
Heart failure in hospital* 1.6 1.8 1.4 1.4 2.0 1.8 0.71 
Heart failure in community 6.0 3.9 5.1 5.1 7.5 8.1 <0.001 
Hypertension treatment 3.1 3.8 3.4 2.2 3.1 3.2 0.56 
Hyperlipidaemia treatment (statins) 11.4 12.3 10.7 11.9 12.8 9.1 0.28 
Total treatmentsa 44.8 46.0 43.3 40.6 50.7 44.6 0.43 
 
Risk factors  
Smoking 3.5 1.3 2.2 2.9 4.6 5.9 <0.0001 
Diabetes -8.5 -5.0 -8.5 -7.5 -9.5 -11.4 <0.001 
Physical activity 2.4 1.8 2.0 2.1 2.7 3.0 0.12 
Systolic blood pressure, mmHg 31.2 31.8 31.6 29.2 34.5 29.7 0.81 
Total cholesterol, mmol/l 15.0 11.0 14.8 11.8 16.7 20.0 <0.0001 
BMI -4.0 -3.4 -3.8 -3.6 -4.6 -4.6 0.16 
Total Risk Factorsa 39.5 37.5 38.4 34.8 44.3 42.7 0.009 
 
DPPs explained by modela 84.3 83.6 81.7 75.4 95.1 87.3  
DPPs not explained by modela 15.7 16.4 18.3 24.6 4.9 12.7  
 
DPP counts  
DPPs explained by modelb 2595 414 460 562 576 581  
T - Due to treatment uptakeb 1380 228 244 302 307 297  
R- Due to risk factor changeb 1215 186 216 259 269 284  
DPPs unexplained by modelb 480 81 103 183 30 85  
Total DPPsb 3075 496 563 744 605 666  
aSub-totals (in rows). 
bDPPs for Scotland (column 2) and Total DPPs (last row) have been rounded to 
nearest 5. 
Abbreviations: CAD, coronary artery disease; SIMD, Scottish index of multiple 
deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial 
infarction; revasc, 
revascularisation; STEMI, ST elevation myocardial infarction. 
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Table L.2 Coronary heart disease deaths prevented or postponed (DPPs) 
amongst women between 2000 and 2010 as percentage of women specific 
total DPPs to be explained, stratified by deprivation quintile 
 
Women 
Treatments by Patient Groups; 
Risk Factors Scotland 
Most 
Affluent SIMDQ2 SIMDQ3 SIMDQ4 
Most 
Deprived P-Value 
Treatments  
STEMI* 1.5 1.7 1.7 1.2 1.5 1.8 0.92 
NSTEACS* 1.4 1.3 1.5 1.2 1.4 1.7 0.51 
Secondary prevention post MI* 6.7 6.7 5.6 5.4 7.6 8.2 0.11 
Secondary prevention post revasc* 1.2 1.2 1.3 0.8 1.4 1.5 0.66 
Chronic stable CAD 8.1 9.1 8.3 7.2 8.0 8.6 0.83 
Heart failure in hospital* 1.3 0.8 1.1 1.2 1.2 2.0 0.10 
Heart failure in community 3.0 2.4 2.1 3.2 3.4 3.9 0.07 
Hypertension treatment 2.2 2.4 2.7 2.0 1.8 2.1 0.43 
Hyperlipidaemia treatment (statins) 15.6 19.2 22.1 14.5 10.4 13.7 <0.0001 
Total treatmentsa 41.0 44.8 46.4 36.6 36.6 43.4 0.10 
 
Risk factors  
Smoking 3.7 1.8 2.5 3.1 4.3 6.4 <0.0001 
Diabetes -7.9 -5.6 -5.5 -6.8 -9.4 -11.6 <0.0001 
Physical activity 1.0 0.8 0.9 0.9 1.1 1.4 0.25 
Systolic blood pressure, mmHg 43.4 44.4 43.7 37.7 46.4 46.0 0.30 
Total cholesterol, mmol/l 1.9 -2.9 -5.2 1.2 7.8 6.5 <0.001 
BMI -4.2 -4.6 -4.5 -3.7 -4.4 -4.0 0.74 
Total Risk Factorsa 37.9 33.8 31.8 32.4 45.9 44.6 <0.0001 
 
DPPs explained by model 78.9 78.6 78.1 69.0 82.5 88.0  
DPPs not explained by model 21.1 21.4 21.9 31.0 17.5 12.0  
 
DPP counts  
DPPs explained by modelb 2130 322 388 447 480 495  
T - Due to treatment uptakeb 1105 183 230 237 213 244  
R- Due to risk factor changeb 1025 138 158 209 267 251  
DPPs unexplained by modelb 570 88 108 201 102 68  
Total DPPsb 2700 409 496 647 582 563  
aSub-totals (in rows). 
bDPPs for Scotland (column 2) and Total DPPs (last row) have been rounded to 
nearest 5. 
Abbreviations: CAD, coronary artery disease; SIMD, Scottish index of multiple 
deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial 
infarction; revasc, 
revascularisation; STEMI, ST elevation myocardial infarction. 
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Tables M. Model fit by age, sex and deprivation quintiles  
 
Table M.1 Total CHD deaths prevented or postponed (DPPs) by age, sex and 
deprivation quintiles (expected deaths had 2000 rates persisted – observed 
deaths in 2010)  
 
 
 National Q1 Q2 Q3 Q4 Q5 
Males 3074 496 563 744 605 666 
Females 2697 409 496 647 582 563 
Male 25-34 3 0 1 -2 0 4 
Male 35-44 16 5 5 0 -6 13 
Male 45-54 144 15 24 41 20 44 
Male 55-64 489 52 74 110 139 114 
Male 65-74 976 124 199 276 159 218 
Male 75-84 1080 180 194 259 234 213 
Male 85+ 366 119 66 61 59 60 
       
Female 25-34 -2 -1 0 -2 0 1 
Female 35-44 4 -2 2 3 -4 5 
Female 45-54 41 6 8 6 19 3 
Female 55-64 209 7 39 38 45 80 
Female 65-74 545 75 95 154 95 126 
Female 75-84 1130 165 202 263 287 214 
Female 85+ 771 160 150 185 140 135 
       
Total 5771 905 1059 1392 1187 1229 
 
 
 
Table M.2 DPPs explained by model by age, sex and deprivation quintiles 
 
 
 National Q1 Q2 Q3 Q4 Q5 
Males 2588 417 459 561 574 578 
Females 2099 318 381 440 473 486 
Male 25-34 3 0 0 0 1 2 
Male 35-44 -4 -1 0 -1 0 -2 
Male 45-54 119 13 18 20 26 41 
Male 55-64 307 34 49 67 75 82 
Male 65-74 539 74 98 117 117 132 
Male 75-84 1041 171 185 231 233 220 
Male 85+ 583 125 109 125 121 103 
       
Female 25-34 0 0 0 0 0 0 
Female 35-44 0 0 0 0 0 0 
Female 45-54 2 3 5 10 10 3 
Female 55-64 8 17 17 23 31 17 
Female 65-74 46 59 82 85 110 59 
Female 75-84 139 169 206 220 215 169 
Female 85+ 123 133 130 134 119 133 
       
Total 4687 735 840 1001 1047 1064 
 
Notes: DPPs explained after adjustment for poly-pharmacy and cumulative risk factor 
reduction 
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Table M.3 Model fita by age, sex and deprivation quintiles 
 
 National Q1 Q2 Q3 Q4 Q5 
Males 84% 84% 82% 75% 95% 87% 
Females 78% 78% 77% 68% 81% 86% 
       
Male 25-34 113% 100% 24% 1% 890% 45% 
Male 35-44 26% 14% 8% 251% 5% 15% 
Male 45-54 83% 86% 78% 50% 128% 93% 
Male 55-64 63% 65% 67% 61% 54% 72% 
Male 65-74 55% 60% 49% 43% 74% 61% 
Male 75-84 96% 95% 95% 89% 100% 103% 
Male 85+ 159% 105% 164% 206% 206% 170% 
       
Female 25-34 24% 0% 100% 0% 151% 29% 
Female 35-44 22% 2% 6% 5% 5% 6% 
Female 45-54 75% 37% 38% 89% 54% 375% 
Female 55-64 46% 113% 44% 44% 51% 39% 
Female 65-74 70% 61% 62% 53% 90% 87% 
Female 75-84 84% 85% 83% 78% 77% 101% 
Female 85+ 83% 77% 89% 70% 95% 89% 
       
Total 81% 81% 79% 72% 88% 87% 
 
aModel fit = absolute % of the total DPPs explained by the model: 
%Model fit = ABSOLUTE (1- ((total DPPs – model DPPs)/total DPPs)) × 100 
 
 
Table M.4 Overall model fit by deprivation quintiles: comparing modelled 
deaths prevented or postponed (DPPs) against observed fall in CHD deaths, 
and 95% uncertainty intervals (UI) 
 
 
Target 
DPPs 
Explained 
DPPs 
Lower UI 
(95%) 
Upper UI 
(95%) 
Explained 
(%) 
Lower 
UI (%) 
Upper 
UI (%) 
SIMDQ1  905 736 545 927 81.3 60.2 102.5 
SIMDQ2 1059 847 623 1071 80.0 58.8 101.1 
SIMDQ3 1392 1006 734 1279 72.3 52.8 91.9 
SIMDQ4 1187 1053 841 1264 88.7 70.9 106.5 
SIMDQ5  1229 1075 856 1294 87.5 69.7 105.3 
Scotland 5771 4717 3700 5735 81.7 64.1 99.4 
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Figure M.1 Model fit by age, gender and deprivation quintiles 
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Table N. Uncertainty analysis: parameter distributions, 
functions and sources  
 
Table N records the type of distribution and associated functions for each of the input 
variables in the IMPACTSEC model. We implemented stochastic uncertainty analysis in 
Excel using Ersatz (version 1.0 available at http://www.epigear.com), an add-in that 
allows probabilistic bootstrapping in Excel.62 Ersatz allows repeated random draws 
from specified distributions for input variables that are used to recalculate iteratively 
the model. It then calculates the 95% uncertainty intervals from the realised values 
of the output variable (deaths prevented or postponed).  For the IMPACTSEC model, 
we calculated the uncertainty intervals based on 1000 draws taking the 95% 
uncertainty intervals as the 2.5th and 97.5th percentiles. Input variables taken from 
external sources (e.g. case fatality rates, beta coefficients and relative risk 
reductions) were randomly drawn from specified distributions but assumed constant 
across deprivation quintiles. Worked examples using Ersatz to estimate uncertainty 
intervals for net treatment DPPs and DPPs attributable to risk factor change are 
shown below Table N. 
 
 
Input parameters Type of distribution and functions (Mean, Standard 
error) 
 
Source  
 
Population 
Population counts and 
CHD deaths stratified by 
age, sex, and Scottish 
Index of Multiple 
Deprivation quintiles 
 
 Population counts (no error) 
 Deaths expected in 2010 had CHD mortality rates in 
2000 persisted (Poisson distribution) 
 
National Records 
Scotland 
Risk factors  
Prevalence/mean 
estimates (pooled data; 
national estimates for 
2000 and 2010) 
 Prevalence estimates (smoking, physical activity, 
diabetes): (Beta distribution: cases, sample-size 
minus cases) 
 
 Continuous variables (Body Mass Index, SBP, total 
cholesterol): (Normal distribution: mean, SE of 
mean) 
 
Scottish Health 
Survey 
RR: smoking 
 
Ersatz RR function (RR, SE ln(RR)): 
RRs and 95% CIs shown in Table J. 
 
Ezzati et al (2005)57 
RR: physical activity 
 
Ersatz RR function (RR, SE ln(RR)): 
RRs and 95% CIs shown in Table J. 
 
 Bull et al (2004)58 
RR: diabetes 
 
Ersatz RR function (RR, SE ln(RR)): 
RRs and 95% CIs shown in Table J.  
Roglic and Unwin 
(2010)11; Huxley et 
al (2006)12 
 
Beta coefficient: Body 
Mass Index 
 
Normal distribution (mean, SE of mean): 
M & F < 45 (0.036,0.005); M & F 45-54 (0.030, 0.004) 
M & F 55-64 (0.023,0.003); M & F 65-74 (0.015, 0.002) 
M & F 75-84 (0.012,0.002); M & F 85+ (0.010, 0.001) 
 
Bogers et al 
(2006)55, James et al 
(2004)56. Parameters 
on the log scale. 
Beta coefficient: SBP 
 
Normal distribution (mean, SE of mean): 
M < 45 (-0.036,0.004); M 45-54 (-0.035,0.004) 
M 55-64 (-0.032,0.003); M 65-74 (-0.027,0.003) 
M 75-84 (-0.021,0.002); M 85+ (-0.016,0.002) 
F < 55 (-0.046, 0.005); F 55-64 (-0.035,0.004) 
Prospective studies 
collaborative meta-
analysis (2002)53. 
Parameters on the 
log scale. 
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F 65-74 (-0.032,0.003); F 75-84 (-0.026,0.003) 
F 85+ (-0.019,0.002) 
 
Beta coefficient: total 
cholesterol 
 
Normal distribution (mean, SE of mean): 
M < 45 (-0.799,0.081); M 45-54 (-0.755,0.077) 
M 55-64 (-0.446,0.046); M 65-74 (-0.236,0.024) 
M 75-84 (-0.117,0.012); M 85+ (-0.083,0.009) 
F < 45 (-0.844,0.086); F 45-54 (-0.734,0.075) 
F 55-64 (-0.431,0.044); F 65-74 (-0.261,0.027) 
F 75-84 (-0.174,0.018); F 85+ (-0.051,0.005) 
 
Prospective studies 
collaborative meta-
analysis (2007)54. 
Parameters on the 
log-scale. 
 
ST elevation myocardial infarction (STEMI) 
 
Eligible patients: 
Emergency admissions 
with a primary diagnosis 
of myocardial infarction. 
(Ratio STEMI/nSTEMI in 
2010 informed by ratio in 
2011 from SMR01. Ratio 
STEMI/nSTEMI in 2000 as 
40/60) 
 
Poisson distribution (admissions) Linked Scottish 
Morbidity Records 
(SMR01) 
Case fatality rate Sample size (n) = emergency admissions for AMI in 1986 
from SMR01 
 
Beta distribution (cases= fatal cases within 1 year , 
non-cases=non fatal cases within 1 year) 
 
Linked Scottish 
Morbidity Records 
(SMR01) for 1986 
Treatment uptake 
 
 Medications and in-hospital CPR: Beta distribution 
(cases = STEMI admissions from MINAP × medication 
uptake, non-cases = STEMI admissions – cases) 
 
 PCI and CABG: Beta distribution (cases = MI 
admissions from SMR01 × PCI/CABG uptake, non-
cases = MI admissions – cases) 
 
 
English MINAP for 
treatment uptake 
(2003 and 2007 for 
start and end year 
respectively); 
SMR01 for number 
of admissions (2000 
and 2010 for start 
and end year 
respectively) 
 
Relative risk reduction:  
 
Ersatz RR function (RRR, SE ln(RRR)): 
 
 
In-hospital CPR M & F (33%,0.103): absolute risk reduction 
 
Tunstall-Pedoe 
(1992) 33 
Thrombolysis 
Aspirin 
Beta-blockers 
Primary PCI 
Primary CABG surgery 
ACE Inhibitors 
 
M & F (0.31,0.298) 
M & F (0.23,0.177) 
M & F (0.04,0.691): assumed lower limit of 1% 
M & F (0.30,0.587) 
M & F (0.39,0.293) 
M & F (0.07,0.435) 
 
 
 
Estess (2002)25  
ISIS-2 (1988)26 
Freemantle (1999) 29   
Keeley (2003)28 
Yusuf (1994)27 
ACE-I MI 
Collaborative Group 
(1998) 30 
Clopidogrel 
 
M & F (0.03,0.457) 
 
Chen (2003)31 
Sabatine (2005)32 
Non-ST segment elevation acute coronary syndrome (NSTEACS) 
 
Eligible patients: 
Emergency admissions 
with a primary diagnosis 
of myocardial infarction 
(Ratio STEMI/nSTEMI in 
2010 informed by ratio in 
2011 from SMR01. Ratio 
STEMI/nSTEMI in 2000 as 
Poisson distribution (nSTEMI + unstable angina 
admissions) 
Linked Scottish 
Morbidity Records 
(SMR01) 
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40/60) or primary 
diagnosis of unstable 
angina 
Case fatality rate Sample size (n) = emergency admissions for unstable 
angina in 1986 from SMR01 
 
Beta distribution (cases = fatal cases within 1 year, 
non-cases = non fatal cases within 1 year) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Treatment uptake 
 
 Medications and in-hospital CPR: Beta distribution 
(cases = NSTEACS admissions × medication uptake, 
non-cases = NSTEACS admissions – cases) 
 
 PCI and CABG: Beta distribution (cases = unstable 
angina admissions from SMR01 × PCI/CABG uptake, 
non-cases = unstable angina admissions – cases) 
 
English MINAP (2003 
and 2010 for start 
and end year 
respectively); 
SMR01 (2000 and 
2010 for start and 
end year 
respectively) 
 
 
Relative risk reduction:  Ersatz RR function (RRR, SE ln(RRR)): 
 
 
 
In-hospital CPR M & F (33%,0.103): absolute risk reduction 
 
Tunstall-Pedoe 
(1992)33 
Aspirin & heparin 
Primary CABG surgery 
Early PCI 
Beta blockers 
Clopidogrel 
ACE Inhibitors 
 
 
M & F (0.33,0.470) 
M & F (0.39,0.293) 
M & F (0.32,0.592) 
M & F (0.04,0.691): assumed lower limit of 1% 
M & F (0.07,0.435) 
M & F (0.07,0.435) 
 
 
Oler (1996)36 
Yusuf (1994)27 
Fox (2005)38 
Freemantle (1999)29 
Yusuf (2001)39 
ACE-I MI 
Collaborative Group 
(1998)30 
Aspirin alone 
 
M & F (0.15,0.139) 
 
Antithrombotic 
Trialists’ Collaboration 
ATC (2002)35 
Platelet glycoprotein 
IIB/IIIA inhibitors 
M & F (0.09,0.530) 
 
Boersma (2002)37 
Secondary prevention post myocardial infarction (MI) 
 
Eligible patients: 
Ever having had a 
myocardial infarction 
since 1981 
 
Poisson distribution (admissions since 1981 from 
SMR01, excluding AMI admissions in 2010 and HF 
admissions since 1981, minus assumed overlap with 
community Heart Failure) 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Case fatality rate Sample size (n) = admissions since 1981 alive on 1st 
January 1995 
 
Beta distribution (cases = fatal cases within 1 year, 
non-cases = non-fatal cases within 1 year) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Treatment uptake 
 
Beta distribution (cases = n  × medication uptake, non-
cases = n – cases) 
 
Primary Care Clinical 
Informatics Unit 
Research (PCCIUR) 
(2000 and 2010 for 
start and end year 
respectively) 
 
 Compliance Sample size (n1) = ever having had MI in PCCIUR in 2010 
with record of medication use: 
 
Beta distribution (cases = n1  × assumed compliance, 
non-cases =  n1  – cases) 
Relative risk reduction:  
 
Ersatz RR function (RRR, SE ln(RRR)):  
Aspirin 
Beta blockers 
ACE Inhibitors 
Statins 
Warfarin 
 
M & F (0.15,0.139) 
M & F (0.23,0.185) 
M & F (0.20,0.177) 
M & F (0.24,0.245) 
M & F (0.22,0.305) 
 
ATC (2002)35 
Freemantle (1999)29  
Flather (2000)40 
Hulten (2006)41 
Anand and Yusuf 
(1999)42 
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Secondary prevention post revascularisation 
 
Eligible patients: 
Ever having had a 
revascularisation 
(excluding admissions for 
MI) 
 
 Poisson distribution (CABG procedures from 1981 
and PTCA procedures from 1989 excluding MI and HF 
admissions) 
 
 Rehabilitation (mortality benefits within last 6 
years only): Poisson distribution (CABG/PTCA 
procedures from 1st January 2005 to 31st December 
2010 excluding HF and MI admissions) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Case fatality rate Sample size (n) = ever having had revascularisation since 
1981 alive on 1st January 1995 (separately for CABG and 
PTCA) 
 
Beta distribution (cases = fatal cases in 1 year, non-
cases = non-fatal cases in 1 year) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Treatment uptake 
 
Beta distribution (cases = n  × medication uptake, non-
cases = n – cases) 
 
PCCIUR (2000 and 
2010 for start and 
end year 
respectively) 
 
 Compliance Sample size (n1) = ever having had revascularisation in 
PCCIUR in 2010 with record of medication use: 
 
Beta distribution (cases = n1  × assumed compliance, 
non-cases =  n1  – cases) 
 
Relative risk reduction:  Ersatz RR function (RRR, SE ln(RRR)): 
 
 
Aspirin 
Beta blockers 
ACE Inhibitors 
Statins 
Rehabilitation 
Warfarin 
 
 
M & F (0.15,0.139) 
M & F (0.23,0.185) 
M & F (0.20,0.177) 
M & F (0.24,0.245) 
M & F (0.26,0.347) 
M & F (0.22,0.305) 
 
 
ATC (2002)35 
Freemantle (1999)29  
Flather (2000)40 
Hulten (2006)41 
Taylor (2004)43 
Anand and Yusuf 
(1999)42 
Chronic stable coronary artery disease 
 
Eligible patients: 
Ever having had chronic 
stable artery disease but 
no myocardial infarction, 
revascularisation or heart 
failure (prior to 
1/1/2010) 
 
Poisson distribution (Population in 2007 × (angina but 
no MI, HF or revascularisation prevalence obtained from 
PCCIUR) minus emergency admissions for unstable 
angina 
Primary Care Clinical 
Informatics Unit 
Research (PCCIUR) 
Case fatality rate Sample size (n) = ever having had angina but no MI in 
PCCIUR in 2010: 
 
Beta distribution (cases = n × CFR estimate, non-cases 
= n – cases) 
 
Wijeysundera et al 
(2010)6 
 
 
Treatment uptake 
 
Beta distribution (cases = n  × medication uptake, non-
cases = n – cases) 
 
PCCIUR (2000 and 
2010 for start and 
end year 
respectively) 
 
 Compliance Sample size (n1) = ever having had angina but no MI in 
PCCIUR in 2010 with record of medication use 
 
Beta distribution (cases = n1  × assumed compliance, 
non-cases =  n1  – cases) 
 
Relative risk reduction: 
Statins 
Aspirin 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.23,0.244) 
M & F (0.15,0.139) 
 
Wilt (2004)45 
ATC (2002)35 
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ACE Inhibitors 
 
 
M & F (0.17,0.177) 
 
Al-Mallah (2006)46 
CABG for chronic stable coronary artery disease (0-6 years) 
 
Eligible patients: 
Ever having had chronic 
stable artery disease but 
no myocardial infarction, 
revascularisation or heart 
failure (prior to 
1/1/2010) 
 
Poisson distribution (estimated count of patients with 
stable coronary artery disease (described above) in 2010 
× (estimated uptake of CABG)): 
 
 2010: Uptake of CABG: (number of CABG 
procedures from 1st Jan 2005 to 31st Dec 
2010)/eligible patients in 2010 
 2000: Uptake of CABG: (number of CABG 
procedures from 1st Jan 1995 to 31st Dec 
2000)/eligible patients in 2000 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Case fatality rate As described in the post-revascularisation group 
 
 
Treatment uptake and 
compliance 
 
Fixed at 100%  
Relative risk reduction: 
CABG (0-5 years) 
 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.39,0.293) 
Yusuf (1994)27 
Heart failure in patients requiring hospitalization 
 
Eligible patients: 
Admissions with a 
primary diagnosis of 
heart failure associated 
with CHD admissions 
 
Poisson distribution (admissions) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
Case fatality rate Sample size (n) = admissions for HF associated with CHD 
admission in 1986 
 
Beta distribution (cases = fatal cases within 1 year, 
non-cases = non-fatal cases within 1 year) 
 
Linked Scottish 
Morbidity Records 
(SMR01) 
 
 
Treatment uptake 
 
 Aspirin: as described in the heart failure in 
community group 
 
Other medications: Sample size (n1) = HF admissions 
from HIS audit: 
 
 Beta distribution (cases = n1 × medication uptake, 
non-cases = n1 – cases) 
 
Heath Improvement 
Scotland (HIS) Audit 
(2008).  
2008 rates taken as 
2010 values. Rates 
assumed 20% lower 
in 2000 (30% lower 
for Beta blockers). 
 
 Compliance Sample size (n2) = HF admissions from HIS audit with 
record of medication use: 
 
Beta distribution (cases = n2  × assumed compliance, 
non-cases = n2  – cases) 
 
Heath Improvement 
Scotland (HIS) Audit 
(2008) 
Relative risk reduction: 
Aspirin 
ACE Inhibitors 
Beta blockers 
Spironolactone 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.15,0.139) 
M & F (0.20,0.177) 
M & F (0.35,0.128) 
M & F (0.30,0.128) 
 
ATC (2002)35 
Flather (2000)40 
Shibata (2001)47  
Pitt (1999)48 
 
Heart failure in the community 
 
Eligible patients: 
Ever having had heart 
failure associated with 
CHD (prior to 1/1/2010) 
Poisson distribution (Population in 2010 × HF 
prevalence obtained from PCCIUR) minus HF hospital 
admissions) 
Primary Care Clinical 
Informatics Unit 
Research (PCCIUR) 
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Case fatality rate Sample size (n) = ever having had HF in PCCIUR in 2010: 
 
Beta distribution (cases = n × CFR estimate, non-cases 
= n – cases) 
 
Wijeysundera et al 
(2010)6 
 
 
Treatment uptake 
 
Beta distribution (cases = n  × medication uptake, non-
cases = n – cases) 
 
PCCIUR (2000 and 
2010 for start and 
end year 
respectively) 
 
 Compliance Sample size (n1) = ever having had HF associated with 
CHD  in PCCIUR in 2010 with record of medication use: 
 
Beta distribution (cases = n1  × assumed compliance, 
non-cases = n1  – cases) 
 
Relative risk reduction: 
Aspirin 
ACE Inhibitors 
Beta blockers 
Spironolactone 
 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.15,0.139) 
M & F (0.20,0.177) 
M & F (0.35,0.128) 
M & F (0.31,0.216) 
 
ATC (2002)35 
Flather (2000)40 
Shibata (2001)47 
Pitt (1999)48 
 
Primary prevention therapies: Statins 
 
Eligible patients: 
Population 
 
Population counts (no error) 
 
National Records 
Scotland 
Treatment uptake 
 
% never having had angina or heart attack and currently 
taking lipid lowering drugs prescribed by a doctor: (Beta 
distribution: cases, sample-size minus cases) 
 
Scottish Health 
Survey 
Case fatality rate Sample size (n) = never having had angina or heart 
attack and currently taking lipid lowering drugs in 2010: 
 
Beta distribution (cases = n × CFR estimate, non-cases 
= n – cases) 
 
Wijeysundera et al 
(2010)6 
 
 
 Compliance Beta distribution (cases = n  × assumed compliance, 
non-cases =  n  – cases) 
 
Scottish Health 
Survey 
Relative risk reduction: 
Statins 
 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.35,0.396) 
 
Pignone (2000)52 
 
Primary prevention therapies: Treatments for high blood pressure 
 
Eligible patients: 
Population 
 
Population counts (no error) 
 
National Records 
Scotland 
Treatment uptake 
 
% never having had angina or heart attack and currently 
taking medication specifically prescribed to treat high 
blood pressure: (Beta distribution: cases, sample-size 
minus cases) 
 
Scottish Health 
Survey 
Case fatality rate Sample size (n) = never having had angina or heart 
attack and currently taking  medication to lower blood 
pressure in 2010: 
 
Beta distribution (cases = n × CFR estimate, non-cases 
= n – cases) 
 
Wijeysundera et al 
(2010)6 
 
 
 Compliance Beta distribution (cases = n  × assumed compliance, 
non-cases =  n  – cases) 
 
Scottish Health 
Survey 
Relative risk reduction: 
Treatments for high blood 
pressure 
 
Ersatz RR function (RRR, SE ln(RRR)): 
M & F (0.13,0.294) 
 
Law (2003)51 
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WORKED EXAMPLES USING ERSATZ FOR UNCERTAINTY ANALYSIS 
 
Below we illustrate our use of Ersatz for uncertainty analysis using males aged 75-84 
in the most deprived quintile in England (~ means “distributed as”). 
 
Note that Examples 1-3 are taken directly from the technical appendix of the 
English IMPACTSEC model1 hence use English data and time points (start year 2000, 
end year 2007) in the calculations. 
 
 
1 Uncertainty analysis for treatments 
 
The net effects of aspirin in the secondary prevention post MI (within the last five 
years) group was calculated as follows: 
 
DPPs (2007) = patient numbers × treatment uptake2007 × compliance × 
relative mortality reduction × 1-year case fatality 
 
= (12 226) × 0.75 × 0.70 × 0.15 × 0.067 ≈ 65 
 
DPPs (2000) = patient numbers × treatment uptake2000 × compliance × 
relative mortality reduction × 1-year case fatality 
 
= (12 226) × 0.59 × 0.70 × 0.15 × 0.067 ≈ 51 
 
Net DPPs were therefore calculated as = DPPs2007 – DPPs2000 ≈ 65 – 51 ≈ 14 
 
Table M above shows the probability distributions and associated Ersatz functions 
used for each input variable in the DPP calculations. For secondary prevention post 
MI we used Poisson (patient numbers); beta (treatment uptake, compliance, and 
case fatality rate) and the Ersatz RR function (relative risk reduction in the 1-year 
case fatality rate owing to treatment). More specifically, for males aged 75-84 in 
IMDQ5, the input values for the uncertainty analysis were as follows: 
 
 Patient numbers ~ Poisson (population in 2007 × post-MI prevalence) minus 
overlap with the heart failure in the community group ~ Poisson (12 226) 
 Treatment uptake in 2007 and 2000 ~ Beta (cases, non-cases) 
If we let n denote ever having had MI in 2007 then cases = (n × uptake of aspirin) 
and non-cases = (n – cases). Cases = (587 × 0.75) = 440; non-cases = (587-440) 
= 147. Treatment uptake in 2007 was therefore ~ Beta (440,147). Likewise, 
treatment uptake in 2000 was ~ Beta (247,169). 
 
 Compliance ~ Beta (cases, non-cases) 
61 
 
If we let n1 denote ever having had MI in 2007 and with record of medication use in 
2007 then cases = (n1 × assumed compliance (0.70)) and non-cases = (n1 – 
cases). Cases = (440 × 0.70) = 308; non-cases = (440-308) = 132. Compliance 
therefore ~ Beta (308,132) 
 
 Relative risk reduction (RRR) ~ Ersatz RR function (RRR, SE ln(RRR)) 
 
where SE and ln denote standard error and natural logarithm, respectively. RRR was 
1-odds ratio for aspirin use in the community taken from ATC (2002) = 1-0.85 = 
0.15; with 95% Confidence Interval (0.11,0.19).35 Using the 95% CIs, the SE of 
ln(RR) was calculated as: 
 
ln(0.19)-ln(0.11)/(1.96×2) = 0.139 
 
Relative risk reduction for aspirin use was therefore ~ Ersatz RR function 
(0.15,0.139) 
 
 Case fatality rate ~ Beta (cases, non-cases) 
Parameter uncertainty around case fatality rates was calculated at the national level 
and assumed constant across all IMD quintiles. If we let n denote ever having had MI 
in 2007 in England then cases = (n × assumed CFR (0.067)) and non-cases = (n – 
cases). Using the GPRD data for males aged 75-84 and assumed CFRs,6 cases = 
(5348 × 0.067) = 358; non-cases = (5348-358) = 4990. Case fatality for the post-
MI group was therefore ~ Beta (358, 4990). 
 
Putting all this together, 10 runs in Ersatz gave the following estimates of each input 
variable randomly drawn from the relevant probability distributions from which we 
calculate the net DPPs for aspirin use in male post myocardial infarction survivors 
aged 75-84 in IMDQ5: 
 
Ten runs in Ersatz to calculate net DPPs for aspirin use in males aged 75-84 
in IMDQ5 in England(post-MI in last 5 years)  
 
Run Numbers Uptake2007 Compliance Relative 
risk 
reduction 
Case 
fatality 
rate 
 
Uptake2000 Net 
DPPs† 
 Probability distributions 
 Poisson Beta Beta RR Beta Beta  
 Col A Col B Col C Col D Col E Col F  
1 12 272 0.737 0.681 0.166 0.068 0.591 13.7 
2 12 297 0.759 0.653 0.184 0.069 0.581 18.3 
3 12 225 0.741 0.687 0.145 0.076 0.607 12.3 
4 12 428 0.736 0.697 0.166 0.069 0.587 14.6 
5 12 252 0.712 0.778 0.189 0.065 0.580 15.5 
6 12 141 0.782 0.727 0.175 0.068 0.588 20.4 
7 12 154 0.777 0.715 0.135 0.066 0.592 14.4 
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8 12 397 0.734 0.698 0.151 0.069 0.591 12.9 
9 12 220 0.723 0.727 0.153 0.070 0.558 15.6 
10 12 427 0.772 0.684 0.186 0.065 0.593 18.5 
Point 
estimate 
12 226 0.75 0.70 0.15 0.067 0.59 14 
† Net DPPs = (A×B×C×D×E) - (A×F×C×D×E) 
 
Uncertainty intervals for treatment contribution DPPs  
In each Ersatz run, net DPPs were calculated for all age-sex-IMD groups and were 
then summed for each medication within each of the 9 mutually exclusive CHD 
patient groups. Each of the nine treatment DPP totals was then multiplied by a 
correction for poly-pharmacy (which varied across patient groups but took the same 
value in each of the 1000 Ersatz runs). An estimate of the total treatment 
contribution to model DPPs was obtained by summing the nine patient group totals.  
 
95% uncertainty intervals from the set of 1000 runs (2.5th and 97.5th percentiles) 
were extracted for the nine treatment totals plus the overall estimate of treatment 
contribution DPPs.  
 
2 Uncertainty analysis for change in binary risk factors 
 
The DPPs attributable to change in smoking prevalence in England over 2000-2007 
was calculated as follows: 
 
DPPs = expected CHD deaths in 2007 (had mortality rates in 2000 remained 
constant) × (PARF2000 – PARF2007) 
 
where PARF = [P × (RR-1)] / [1 + P × (RR-1)]; P is the prevalence of the risk factor 
and RR is the relative risk for CHD mortality associated with risk factor presence. 
For the three binary risk factors (smoking, diabetes, and physical activity) we used 
the following probability distributions: Poisson (expected deaths); beta (risk factor 
prevalence) and the Ersatz RR function (relative risk reduction owing to elimination 
of exposure). More specifically, for males aged 75-84 in IMDQ5, the input values for 
the uncertainty analysis were as follows: 
 
 Expected CHD deaths in 2007  ~ Poisson (population in 2007 × CHD mortality 
rates in 2000) ~ Poisson (4236) 
 Estimates of smoking prevalence ~ Beta (cases, non-cases) 
If we let n denote the number of Health Survey for England male respondents aged 
75-84 in IMDQ5 over all years from 2000 to 2007 (i.e. pooled data) then cases = (n 
× estimate of smoking prevalence) and non-cases = (n – cases). Cases = (439 × 
0.160) = 70; non-cases = (439-70) = 369. Smoking prevalence over 2000-2007 
therefore ~ Beta (70,369). The same method was used for a pooled estimate of 
smoking prevalence at the national level. Smoking prevalence over 2000-2007 in 
England for males aged 75-84 ~ Beta (283,2710) 
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National estimates of smoking prevalence were calculated in the start and final years 
of the model (2000 and 2007). Smoking prevalence in England for males aged 75-84 
in 2000 ~ Beta (22,225); smoking prevalence in England for males aged 75-84 in 
2007 ~ Beta (26,216) 
 
 Increased relative risk attributable to smoking ~ Ersatz RR function (RR, SE 
ln(RR)) 
 
where RR was taken from the CPS-II study but modified to fit into the ten-year age 
bands used for IMPACTSEC.57 For males aged 75-84, RR for smoking = 1.31 with 95% 
CI (1.11,1.56). Using the 95% CI the SE of ln(RR) was calculated as follows: 
 
ln(1.56)-ln(1.11)/(1.96×2) = 0.088 
 
The relative risk for smoking in males aged 75-84 was therefore ~ Ersatz RR function 
(1.31, 0.088) 
 
Putting all this together, ten runs in Ersatz gave the following estimates of each input 
variable randomly drawn from the relevant probability distributions from which we 
calculate DPPs from the change in smoking prevalence over 2000-2007 in males 
aged 75-84 in IMDQ5: 
 
Ten runs in Ersatz to calculate DPPs for change in smoking prevalence over 
2000-2007 in males aged 75-84 in IMDQ5 in England 
 
Run Expected 
deaths 
Pooled % 
smokeIMD 
Pooled % 
smokeEng 
Relative 
risk 
% smoke 
in 2000Eng 
% smoke 
in 2007Eng 
 
 
DPPsa 
 Probability distributions 
 Poisson Beta Beta RR Beta Beta  
 Col A Col B Col C Col D Col E Col F  
1 4258 0.141 0.103 1.072 0.095 0.127 -13.3 
2 4207 0.175 0.092 1.231 0.082 0.101 -33.2 
3 4294 0.169 0.097 1.461 0.089 0.096 -23.5 
4 4130 0.161 0.092 1.377 0.080 0.118 -94.5 
5 4294 0.154 0.093 1.169 0.108 0.083 28.7 
6 4259 0.169 0.100 1.337 0.067 0.112 -101.4 
7 4251 0.205 0.098 1.094 0.069 0.131 -50.4 
8 4290 0.169 0.106 1.371 0.095 0.092 6.3 
9 4310 0.135 0.094 1.299 0.079 0.093 -25.1 
10 4402 0.151 0.090 1.158 0.050 0.100 -56.2 
Point 
estimate 
4236 0.160 0.095 1.31 0.089 0.108 -38 
a Intermediate steps in calculating DPPs as follows: 
PARF using pooled data (IMD) = (B × (D-1))/(B × (D-1)+1);  
PARF using pooled data (England) = (C × (D-1))/(C × (D-1)+1).  
SEC gradient calculated as the ratio of these two quantities. 
PARF in 2000 (England) = (E × (D-1))/(E × (D-1)+1);  
PARF in 2007 (England) = (F × (D-1))/(F × (D-1)+1) 
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DPPs = A × ((PARF in 2000 (England) × SEC gradient) - ((PARF in 2007 (England) × 
SEC gradient) 
 
Uncertainty intervals for binary risk factor DPPs  
Within each run, DPPs were calculated for all age-sex-IMD groups and were then 
summed within each of the three binary risk factors. 95% uncertainty intervals from 
the set of 1000 runs (2.5th and 97.5th percentiles) were extracted for each risk factor 
total. The 95% uncertainty intervals were then scaled down using an overall 
correction for cumulative risk reduction (See Section 1.3 and Table D). 
 
3 Uncertainty analysis for change in continuous risk factors 
 
DPPs attributable to change in mean levels of systolic blood pressure (SBP) in 
England over 2000-2007 were calculated as follows: 
 
DPPs = expected CHD deaths in 2007 (had mortality rates in 2000 remained 
constant) × absolute risk factor reduction between 2000 and 2007 × 
regression coefficient exponentiated 
 
For continuous risk factors (SBP, total cholesterol, fruit and vegetable consumption, 
and BMI) we used the Poisson (expected deaths) and Normal probability distributions 
(mean risk factor levels and the beta coefficients quantifying the change in CHD 
mortality resulting from a one-unit absolute change in risk factor level between 2000 
and 2007). The input values for the uncertainty analysis were as follows: 
 
 Expected deaths  ~ Poisson (population in 2007 × CHD mortality rates in 
2000) ~ Poisson (4236) 
 Estimates of SBP levels ~ Normal (mean, SE mean) 
For males aged 75-84 in IMDQ5 mean SBP levels using all Health Survey for England 
data over the time period 2000 to 2007 ~ Normal (mean = 143.1 mmHg, SE = 
1.51). The SE was estimated in Stata Version 11.1 to account for the complex survey 
design. Likewise, for males aged 75-84 in England mean SBP levels over 2000-2007 
~ Normal (mean = 141.0, SE = 0.49). The SEC gradient in mean SBP was computed 
as the ratio of these two quantities.  
 
National estimates for 2000 and 2007 were used to estimate absolute change in SBP 
over the seven year period. In 2000, mean SBP for males aged 75-84 in England was 
~ Normal (mean = 141.9, SE = 1.39); for 2007 mean SBP ~ Normal (mean = 135.8, 
SE = 1.48). 
 
 Beta coefficients ~ Normal (mean, SE) 
where the beta coefficient for SBP (on the logarithmic scale) taken from the PSC 
study for males aged 75-84 was -0.0212 with 95% CI (-0.0170,-0.0255) 53. Using 
the 95% CIs the SE of the beta coefficient was calculated as follows: 
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(-0.0170) - (-0.0255)/(1.96×2) = 0.0022 
 
The beta coefficient for SBP for males aged 75-84 in IMDQ5 was therefore ~ Normal 
(mean = -0.0212, SE = 0.0022). 
 
Putting all this together, ten runs in Ersatz gave the following estimates of each input 
variable drawn from the relevant probability distributions from which we calculated 
DPPs from the absolute change in mean SBP over 2000-2007 in males aged 75-84 in 
IMDQ5: 
 
Ten runs in Ersatz to calculate DPPs for change in mean SBP levels over 
2000-2007 in males aged 75-84 in IMDQ5 in England 
 
Run Expected 
deaths 
Pooled 
SBPIMD 
Pooled 
SBPEngland 
Beta  SBP in 
2000Eng 
SBP in 
2007Eng 
 
DPPsa 
 Probability distributions 
 Poisson Normal Normal Normal Beta Beta  
 Col A Col B Col C Col D Col E Col F  
1 4168 142.7 141.8 -0.022 138.0 133.9 366.1 
2 4149 146.2 142.1 -0.018 142.8 136.3 476.0 
3 4075 143.5 141.7 -0.021 143.0 134.0 697.5 
4 4225 144.2 140.6 -0.019 139.8 136.7 256.8 
5 4240 142.8 140.7 -0.021 140.4 137.0 301.5 
6 4194 143.8 141.8 -0.021 140.8 134.9 502.2 
7 4234 144.1 140.5 -0.025 144.4 134.0 1012.8 
8 4126 142.0 141.9 -0.023 141.3 132.2 778.0 
9 4291 145.3 141.7 -0.019 140.2 135.2 389.1 
10 4264 141.5 140.8 -0.025 138.4 137.6 84.0 
Point 
estimate 
4236 143.1 141.0 -0.0212 141.9 135.8 524 
a Intermediate steps in calculating DPPs as follows: 
SEC gradient calculated as B/C.  
Absolute change in mean SBP calculated as (E × SEC gradient) – (F × SEC 
gradient) 
 
DPPs = (1-exp(D × (absolute change in mean SBP))) × A 
 
Uncertainty intervals for continuous risk factor DPPs  
Within each run, DPPs were calculated for all age-sex-IMD groups and were then 
summed within each of the four continuous risk factors. For systolic blood pressure 
and total cholesterol we then subtracted the DPPs calculated in the treatment 
(primary prevention) component of the model from the DPPs calculated in the risk 
factor component (See Section 1.4.6). 95% uncertainty intervals were then 
calculated from the set of 1000 runs (taken from the 2.5th and 97.5th percentiles) for 
the four continuous risk factor DPP totals. These were then scaled down using an 
overall correction for cumulative risk reduction. 
 
Uncertainty intervals for total risk factor contribution DPPs  
Within each run, the total risk factor contribution to model DPPs was obtained by 
summation of six risk factor DPPs totals (within each age-sex-IMD group). A 95% 
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uncertainty interval for the overall risk factor contribution was obtained from the set 
of 1000 runs by taking the 2.5th and 97.5th percentiles. These lower and upper limits 
were then scaled down using the correction for cumulative risk reduction. 
 
Uncertainty intervals for total model DPPs (changes in treatment uptake and risk 
factors) 
Within each run, we also calculated an estimate of the total model DPPs by 
summation of the treatment contribution DPPs and the risk factor contribution DPPs 
after adjustment for cumulative risk reduction. The standard deviation of the 
estimated total model DPPs over the set of 1000 runs was extracted for England and 
each deprivation quintile. The 95% uncertainty intervals for total model DPPs were 
then obtained as follows: 
 
Lower limit = estimate – (1.96 × standard deviation) 
Upper limit = estimate + (1.96 × standard deviation) 
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Table O.  Assumptions and overlap adjustments used in the 
IMPACTSEC model 
 
Potential overlaps between patient groups with chronic CHD 
 
 
Therefore, to avoid double counting, potential overlaps between different groups of 
patients were identified and appropriate adjustments made by subtracting one group 
from another. For instance, we can subtract the number of severe heart failure 
patients treated in hospital from the total number of heart failure patients in the 
community (because community heart failure patients could be admitted to hospital 
on one or more occasions). As far as possible the linked Scottish Morbidity Records 
(SMR01) and death record dataset has been used to assign individual patients to 
only one of the nine disease states; thus avoiding overlaps. Additionally patients 
within the PCCIUR dataset were assigned to mutually exclusive groups. In both the 
SMR01 and the PCCIUR a hierarchy of allocation based on case-fatality was created 
to assign an individual patient (existing in multiple patient groups) to just one 
patient group (the one with the highest case fatality). The hierarchy structure used is 
shown in Figure O.1.  
 
Where this process is not possible then assumptions on overlap adjustment were 
made showing how potential overlaps were accounted for; these are shown in the 
table below. Patient overlaps for the final year of the model are shown in Figure O.2.  
 
Post MI 
Post 
revascularisation 
Heart failure in  
the community 
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Table O.1 Main assumptions and overlap adjustments used in the IMPACTSEC 
model 
 
Treatment category Assumptions and overlap adjustments Justification 
Post-AMI  Assume 25% already counted in the heart failure in 
community group. This was reduced from 30% as all 
patients with HF admissions since 1981 had been 
excluded from this group 
 
Weir (2006)63 
Angina in the 
community 
Start with the total numbers with angina in the 
community (without MI, HF or revascularisation) 
based on PCCIUR prevalence from mutually exclusive 
groups. Then deduct persons already treated for 
unstable angina in hospital 
 
Capewell (2000)2 
Heart failure in the 
community 
Based on PCCIUR prevalence of patients with HF 
associated with CHD from mutually exclusive groups. 
Then deduct persons treated for severe heart failure 
in the hospital (already counted) 
 
 
Fall in population blood 
pressure 
Estimate the number of DPPs by hypertension 
treatment. Then subtract this from the total DPPs 
attributed to the secular fall in population blood 
pressure 
 
Capewell (1999)3 
Capewell (2000)2 
Fall in population total 
cholesterol 
Estimate the number of DPPs by cholesterol lowering 
medication. Then subtract this from the total DPPs 
attributed to the secular fall in population cholesterol 
 
   
AMI denotes acute myocardial infarction, CHD coronary heart disease, DPPs deaths prevented or 
postponed, PCCIUR Primary Clinical Care Informatics Unit Research. 
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Figure O.1 Assignment of patients and overlaps for Scottish IMPACTSEC (2010) 
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Overlap community 
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Figure O.2 Patient overlaps for IMPACTSEC with patient numbers for 2010 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MI denotes myocardial infarction; STEMI ST-segment elevation; NSTE-ACS non-ST segment elevation; CHD Coronary  
heart disease; CABG Coronary artery bpass grafting; PTCA Percutaneous transluminal coronary angioplasty. Figures in 
bold represent patient numbers used in IMPACTSEC model (i.e. minus relevant overlaps). 
 
 
Hospital 
admissions 
(mutually 
exclusive 
groups) 
MI (7140) 
STEMI (2502) 
NSTE-ACS (9462) 
((NSTEMI 4638)+(UA 4824)) 
Unstable 
angina 
(4824) 
Heart failure associated with CHD (3644) 
Primary 
prevention 
 
(population 
≈ 3.5 
million) 
Statins for hypercholesterolemia (557,162) 
 
Anti-hypertensive medication (673,032) 
 
 
 
Secondary 
prevention 
 
historical 
hospital 
admissions 
Post MI  
TOTAL (80,262) 
MI, no HF (60197) Overlap with HF 
in community 
(80,262 × 0.25) 
Angina, no MI  
TOTAL (77,218) 
HF in the 
community 
TOTAL (19,868) 
Angina, no MI (72,394) Admissions for 
UA (4824) 
HF associated with CHD (16,224) Admissions for 
CHD related HF 
(3644) 
Post CABG survivors since 1981 
 (21,270) 
Post PTCA survivors since 1989 
 (19,025) 
Secondary 
prevention 
 
Primary care 
records 
(PCCIUR) 
35% 
65% 
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Table P. ‘Fixed gradients’ for measuring risk factor change 
between two time points for deprivation quintiles	
 
The sample size of the Scottish Health Survey (SHeS), roughly 6 to 8000 adults in 
each age-sex group aged 25 years and over, was not large enough to provide 
accurate/precise estimates of risk factor levels, and hence rates of change over time 
by age, sex, and deprivation quintiles (70 groups in total). Therefore, data from all 
surveys were pooled and a ‘fixed gradient approach’ was used for estimating risk 
factor change as key inputs into the regression and PARF deaths prevented or 
postponed calculations, as used in the English IMPACTSEC model1. 
 
The fixed gradient approach was based on the assumption that changes in pace and 
direction for each deprivation quintile were similar and therefore, most accurately 
measured by the overall national rates of change (across 14 age-sex groups). If this 
assumption holds, then relatively stable and plausible estimates for each quintile 
could be derived by scaling the national age-sex risk factor levels up or down using a 
fixed ratio/gradient.  
 
The fixed gradient approach has the advantage of reducing the number of data 
breaks to a maximum of 14 (age by sex) for any single SHeS year and instead of 
discarding the survey information in the intermediate years, used the whole data 
series to improve and stabilise the 70 estimates. The disadvantage was that the 
assumption of a fixed gradient for each age-by-sex group remaining constant over 
time may not hold (e.g. the difference in risk factor level between a deprivation 
quintile and the national rate may be considerably larger in 2000 than in 2010). It 
was concluded that substantial relative changes over such a short period were 
possible but unlikely. 
 
An illustrative example using data from the English IMPACTSEC model,1 using the 
population-attributable risk fraction (PARF), is set out below.   
 
 
EXAMPLE: Fixed gradient for change in smoking prevalence in men aged 45-
54 in England 
 
Step 1 
Using the pooled 2000-7 HSfE data the national estimate of current smoking was 
25.7% for men aged 45-54. Estimates by deprivation quintile ranged from 14.0% for 
men in the most affluent quintile (IMDQ1) to 46.5% in the most deprived (IMDQ5). 
The relative risk (RR) of smoking taken from the CPS-II study was 3.0457. Using the 
smoking prevalence (P) and the RR (assumed the same across deprivation quintiles) 
we calculated the PARF for England as a whole and each deprivation quintile using 
the formula: 
 
PARF = [P × (RR - 1)]/[1 + P × (RR - 1)] 
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Applying step 1: Calculate the PARF gradient using 2000-7 pooled survey data 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7
IMDQ2 
2000-7
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
Proportion smokers (P) 0.2569 0.1398 0.1949 0.2668 0.2882 0.4652 
RR 3.04 3.04 3.04 3.04 3.04 3.04 
PARF 0.3427 0.2258 0.2819 0.3510 0.3671 0.4846 
Gradient in PARF 1 0.659 0.823 1.024 1.071 1.414 
  
The PARF calculated using pooled data at the national level was then set notionally to 
one, and the corresponding values for each deprivation quintile re-indexed to be 
below or above one. For example, the pooled gradient in the PARF for men aged 45-
54 in Q1 was estimated to be 0.2258/0.3427 = 0.659.  
 
Step 2 
Using the HSfE data for the start and final year of the model we then derived the 
national PARF for 14 age-by-sex groups. The national PARF for men aged 45-54 
based on prevalence (P) of 28.3% and RR of 3.04 in 2000 was 0.3662; a prevalence 
of 25.1% in 2007 gave a PARF of 0.3385.   
 
Applying step 2: Calculate the national PARF in base and final year 
Men 45-54 England 
2000 
England 
2007 
Proportion smokers (P) 0.2832 0.2508 
RR 3.04 3.04 
PARF 0.3662 0.3385 
 
 
 
Step 3 
The fixed gradient (Step 1) was then applied to the national PARF (Step 2) to 
produce estimates of the PARF for each deprivation quintile, separately for the base 
and final years of the model. For example, for men aged 45-54 in Q1 the 2000 
estimate of the PARF was equal to 0.3662 (national PARF) multiplied by the gradient 
(0.659), to give an estimate of 0.2413. The 2007 estimate was equal to 0.3385 
(national PARF) multiplied by the fixed gradient (0.659), to give an estimate of 
0.2230. 
 
Applying step 3: Estimate the PARF by deprivation quintiles for single years 2000 and 
2007 using fixed gradient 
 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7 
IMDQ2 
2000-7 
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
PARF 2000 0.3662 0.2413 0.3012 0.3751 0.3923 0.5179 
PARF 2007 0.3385 0.2230 0.2784 0.3467 0.3626 0.4787 
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Step 4: Calculating the DPPs 
 
The formula for calculating DPPs using the change in PARF approach was as follows: 
 
Expected CHD deaths in 2007 (had mortality rates in 2000 remained constant)  × 
difference between the PARF in 2000 and 2007 
 
Expected CHD deaths in 2007  × (PARF2000 – PARF2007) 
 
Applying step 4: Estimate the DPPs due to change in PARF between 2000 and 2007 
Men 45-54 England 
2000-7 
IMDQ1 
2000-7 
IMDQ2 
2000-7 
IMDQ3 
2000-7 
IMDQ4 
2000-7 
IMDQ5 
2000-7 
CHD mortality rate 
(2000)a 
0.9131 0.5434 0.6644 0.8177 1.1173 1.6448 
Population (2007) 3284291 736444 700676 660481 611424 575266 
Aded deaths (2007) 3035 400 466 540 683 946 
PARF 2000 0.3662 0.2413 0.3012 0.3751 0.3923 0.5179 
PARF 2007 0.3385 0.2230 0.2784 0.3467 0.3626 0.4787 
DPPs in 2007 91b 7 11 15 20 37 
a Rate per 1000 
b The total DPPs for England was based on the sum of the DPPs across the 
deprivation quintiles. 
 
The ‘fixed gradient’ approach has the advantage of reducing the number of data 
breaks to a maximum of 14 (age by sex) for any single year and instead of 
discarding the survey information in the intermediate years, as other methods do, 
used the whole data series to improve and stabilise the 70 estimates. The 
disadvantage was that the assumption of a fixed gradient for each age-by-sex group 
remaining constant over time may not hold (e.g. the difference in risk factor level 
between a deprivation quintile and the national rate may be considerably larger in 
2000 than in 2007).  Furthermore, we concluded that substantial relative changes 
over such a short period were possible but unlikely.  
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